{ "slug": "summit-therapeutics", "canonical_name": "Summit Therapeutics", "website": null, "ats": "greenhouse", "top_startup": false, "top_startup_sources": [], "total_active_jobs": 25, "verified_benefits": { "parental_leave_weeks": null, "non_birth_parent_leave_weeks": null, "source_url": null, "verified_count": 0, "last_verified": null }, "awards": null, "jobs": [ { "id": "81a77d2f703c8a734b1f4152e2061b4b", "title": "Executive Director, Regulatory Affairs – Global Regulatory Leader", "employer_name": "Summit Therapeutics", "employer_slug": "summit-therapeutics", "location_text": "(Remote US)", "country": "US", "employment_type": "unknown", "remote_status": "remote", "remote_status_source": null, "remote_status_enriched_at": null, "days_in_office": 0, "timezone_overlap_hours": 6, "salary_min": 231000, "salary_max": 285000, "salary_min_source": null, "salary_max_source": null, "salary_currency": "USD", "salary_type": "total_comp", "salary_type_source": null, "salary_type_enriched_at": null, "salary_period": "year", "base_salary_min": null, "base_salary_max": null, "salary_disclosed": true, "equity_included": false, "equity_included_source": null, "equity_type": [ "none" ], "k401_match": null, "match_401k_pct": null, "match_401k_pct_source": null, "k401_match_source_url": null, "k401_match_source_fields": [], "k401_contribution_source_url": null, "k401_contribution_source_fields": [], "profit_sharing": false, "bonus_offered": true, "mental_health_support": null, "childcare_subsidy": null, "fertility_family_building_benefits": null, "adoption_assistance_offered": null, "surrogacy_assistance_offered": null, "learning_budget_offered": null, "relocation_assistance": null, "top_startup_sources": [], "posted_at": "2026-06-05T14:46:04.000Z", "apply_url": "https://job-boards.greenhouse.io/summittherapeutics/jobs/4274378009", "apply_url_verified": false, "ats": "greenhouse", "url_last_checked_alive": null, "removed_at": null, "description_excerpt": "Executive Director, Regulatory Affairs – Global Regulatory Leader (Remote US) About Summit: Summit Therapeutics Inc. is a biopharmaceutical oncology company with a mission focused on improving quality of life, increasing potential duration of life, and resolving serious unmet medical needs. At Summit, we believe in building a team of world class professionals who are passionate about this mission, and it is our people who drive this mission to reality. Summit's core values include integrity, passion for excellence, purposeful urgency, collaboration, and our commitment to people. Our employees are truly the heart and soul of our culture, and they are invaluable in shaping our journey toward excellence. Summit's team is inspired to touch and help change lives through Summit's clinical studies in the field of oncology. Summit has multiple global Phase 3 clinical studies, including: Non-small Cell Lung Cancer (NSCLC) - HARMONi: Phase 3 clinical study which was intended to evaluate ivonescimab combined with chemotherapy compared to placebo plus chemotherapy in patients with EGFR-mutated, locally advanced or metastatic non-squamous NSCLC who were previously treated with a 3rd generation EGFR TKI. - HARMONi-3: Phase 3 clinical study which is intended to evaluate ivonescimab combined with chemotherapy compared to pembrolizumab combined with chemotherapy in patients with first-line metastatic NSCLC. - HARMONi-7: Phase 3 clinical study which is intended to evaluate ivonescimab monotherapy compared to pembrolizumab monotherapy in patients with first-line metastatic NSCLC. Colorectal Cancer (CRC) - HARMONi-GI3: Phase 3 clinical study intended to evaluate ivonescimab in combination with chemotherapy compared with bevacizumab plus", "parental_leave_weeks": null, "non_birth_parent_leave_weeks": null, "parental_leave_weeks_source": null, "non_birth_parent_leave_weeks_source": null, "parental_leave_source_url": null, "pto_days": null, "unlimited_pto": false, "sabbatical_eligible": false, "family_friendly_score": 52, "benefit_verified": false, "benefit_last_verified": null, "hire_states_allowed": [], "state_eligibility_source": null, "state_eligibility_enriched_at": null, "llm_quality_pass_at": null, "seniority": "staff_plus", "years_experience_min": 15, "years_experience_max": null, "role_function": "engineering", "employer_industry": null, "employer_size": null, "quality_score": 55, "travel_pct": 5, "requires_shift": null, "shift_type": "unknown", "shift_type_source": null, "weekend_work": "unknown", "weekend_work_source": null, "relocation_assistance_source": null, "contractor_w2": "unknown", "required_timezone": null, "fertility_family_building_benefits_source": null, "mental_health_support_source": null, "adoption_assistance_offered_source": null, "childcare_subsidy_source": null, "learning_budget_offered_source": null, "surrogacy_assistance_offered_source": null, "cover_letter_required": null, "cover_letter_required_source": null, "assessment_required": null, "assessment_required_source": null, "application_deadline": null, "application_deadline_source": null, "visa_sponsorship": false, "us_citizenship_required": false, "security_clearance": "none", "education_required": "doctorate", "roll_up_count": null, "roll_up_total_locations": null, "explanations": [] }, { "id": "4c10bf45a7eb963ac29116b93548a466", "title": "Director, Portfolio Strategy", "employer_name": "Summit Therapeutics", "employer_slug": "summit-therapeutics", "location_text": "Palo Alto, CA (US)", "country": "US", "employment_type": "unknown", "remote_status": "unspecified", "remote_status_source": null, "remote_status_enriched_at": null, "days_in_office": null, "timezone_overlap_hours": 6, "salary_min": 200000, "salary_max": 250000, "salary_min_source": null, "salary_max_source": null, "salary_currency": "USD", "salary_type": "total_comp", "salary_type_source": null, "salary_type_enriched_at": null, "salary_period": "year", "base_salary_min": null, "base_salary_max": null, "salary_disclosed": true, "equity_included": false, "equity_included_source": null, "equity_type": [ "none" ], "k401_match": null, "match_401k_pct": null, "match_401k_pct_source": null, "k401_match_source_url": null, "k401_match_source_fields": [], "k401_contribution_source_url": null, "k401_contribution_source_fields": [], "profit_sharing": false, "bonus_offered": true, "mental_health_support": null, "childcare_subsidy": null, "fertility_family_building_benefits": null, "adoption_assistance_offered": null, "surrogacy_assistance_offered": null, "learning_budget_offered": null, "relocation_assistance": null, "top_startup_sources": [], "posted_at": "2026-06-05T13:19:12.000Z", "apply_url": "https://job-boards.greenhouse.io/summittherapeutics/jobs/4274498009", "apply_url_verified": false, "ats": "greenhouse", "url_last_checked_alive": null, "removed_at": null, "description_excerpt": "Director, Portfolio Strategy Palo Alto, CA (US) About Summit: Summit Therapeutics Inc. is a biopharmaceutical oncology company with a mission focused on improving quality of life, increasing potential duration of life, and resolving serious unmet medical needs. At Summit, we believe in building a team of world class professionals who are passionate about this mission, and it is our people who drive this mission to reality. Summit's core values include integrity, passion for excellence, purposeful urgency, collaboration, and our commitment to people. Our employees are truly the heart and soul of our culture, and they are invaluable in shaping our journey toward excellence. Summit's team is inspired to touch and help change lives through Summit's clinical studies in the field of oncology. Summit has multiple global Phase 3 clinical studies, including: Non-small Cell Lung Cancer (NSCLC) - HARMONi: Phase 3 clinical study which was intended to evaluate ivonescimab combined with chemotherapy compared to placebo plus chemotherapy in patients with EGFR-mutated, locally advanced or metastatic non-squamous NSCLC who were previously treated with a 3rd generation EGFR TKI. - HARMONi-3: Phase 3 clinical study which is intended to evaluate ivonescimab combined with chemotherapy compared to pembrolizumab combined with chemotherapy in patients with first-line metastatic NSCLC. - HARMONi-7: Phase 3 clinical study which is intended to evaluate ivonescimab monotherapy compared to pembrolizumab monotherapy in patients with first-line metastatic NSCLC. Colorectal Cancer (CRC) - HARMONi-GI3: Phase 3 clinical study intended to evaluate ivonescimab in combination with chemotherapy compared with bevacizumab plus chemotherapy. Ivonescimab is", "parental_leave_weeks": null, "non_birth_parent_leave_weeks": null, "parental_leave_weeks_source": null, "non_birth_parent_leave_weeks_source": null, "parental_leave_source_url": null, "pto_days": null, "unlimited_pto": false, "sabbatical_eligible": false, "family_friendly_score": 44, "benefit_verified": false, "benefit_last_verified": null, "hire_states_allowed": [], "state_eligibility_source": null, "state_eligibility_enriched_at": null, "llm_quality_pass_at": null, "seniority": "staff_plus", "years_experience_min": 8, "years_experience_max": 12, "role_function": "product", "employer_industry": null, "employer_size": null, "quality_score": 55, "travel_pct": 25, "requires_shift": null, "shift_type": "unknown", "shift_type_source": null, "weekend_work": "unknown", "weekend_work_source": null, "relocation_assistance_source": null, "contractor_w2": "unknown", "required_timezone": null, "fertility_family_building_benefits_source": null, "mental_health_support_source": null, "adoption_assistance_offered_source": null, "childcare_subsidy_source": null, "learning_budget_offered_source": null, "surrogacy_assistance_offered_source": null, "cover_letter_required": null, "cover_letter_required_source": null, "assessment_required": null, "assessment_required_source": null, "application_deadline": null, "application_deadline_source": null, "visa_sponsorship": false, "us_citizenship_required": false, "security_clearance": "none", "education_required": "doctorate", "roll_up_count": null, "roll_up_total_locations": null, "explanations": [] }, { "id": "ecb977336ca320c11a19901b2063e5ee", "title": "Corporate Counsel, Clinical Contracts", "employer_name": "Summit Therapeutics", "employer_slug": "summit-therapeutics", "location_text": "Remote (US)", "country": "US", "employment_type": "contract", "remote_status": "remote", "remote_status_source": null, "remote_status_enriched_at": null, "days_in_office": 0, "timezone_overlap_hours": 6, "salary_min": 158000, "salary_max": 185000, "salary_min_source": null, "salary_max_source": null, "salary_currency": "USD", "salary_type": "total_comp", "salary_type_source": null, "salary_type_enriched_at": null, "salary_period": "year", "base_salary_min": null, "base_salary_max": null, "salary_disclosed": true, "equity_included": false, "equity_included_source": null, "equity_type": [ "none" ], "k401_match": null, "match_401k_pct": null, "match_401k_pct_source": null, "k401_match_source_url": null, "k401_match_source_fields": [], "k401_contribution_source_url": null, "k401_contribution_source_fields": [], "profit_sharing": false, "bonus_offered": true, "mental_health_support": null, "childcare_subsidy": null, "fertility_family_building_benefits": null, "adoption_assistance_offered": null, "surrogacy_assistance_offered": null, "learning_budget_offered": null, "relocation_assistance": null, "top_startup_sources": [], "posted_at": "2026-05-27T15:38:56.000Z", "apply_url": "https://job-boards.greenhouse.io/summittherapeutics/jobs/4259982009", "apply_url_verified": false, "ats": "greenhouse", "url_last_checked_alive": null, "removed_at": null, "description_excerpt": "Corporate Counsel, Clinical Contracts Remote (US) About Summit: Summit Therapeutics Inc. is a biopharmaceutical oncology company with a mission focused on improving quality of life, increasing potential duration of life, and resolving serious unmet medical needs. At Summit, we believe in building a team of world class professionals who are passionate about this mission, and it is our people who drive this mission to reality. Summit's core values include integrity, passion for excellence, purposeful urgency, collaboration, and our commitment to people. Our employees are truly the heart and soul of our culture, and they are invaluable in shaping our journey toward excellence. Summit's team is inspired to touch and help change lives through Summit's clinical studies in the field of oncology. Summit has multiple global Phase 3 clinical studies, including: Non-small Cell Lung Cancer (NSCLC) - HARMONi: Phase 3 clinical study which was intended to evaluate ivonescimab combined with chemotherapy compared to placebo plus chemotherapy in patients with EGFR-mutated, locally advanced or metastatic non-squamous NSCLC who were previously treated with a 3rd generation EGFR TKI. - HARMONi-3: Phase 3 clinical study which is intended to evaluate ivonescimab combined with chemotherapy compared to pembrolizumab combined with chemotherapy in patients with first-line metastatic NSCLC. - HARMONi-7: Phase 3 clinical study which is intended to evaluate ivonescimab monotherapy compared to pembrolizumab monotherapy in patients with first-line metastatic NSCLC. Colorectal Cancer (CRC) - HARMONi-GI3: Phase 3 clinical study intended to evaluate ivonescimab in combination with chemotherapy compared with bevacizumab plus chemotherapy. Ivonescimab is an", "parental_leave_weeks": null, "non_birth_parent_leave_weeks": null, "parental_leave_weeks_source": null, "non_birth_parent_leave_weeks_source": null, "parental_leave_source_url": null, "pto_days": null, "unlimited_pto": false, "sabbatical_eligible": false, "family_friendly_score": 52, "benefit_verified": false, "benefit_last_verified": null, "hire_states_allowed": [], "state_eligibility_source": null, "state_eligibility_enriched_at": null, "llm_quality_pass_at": null, "seniority": "mid", "years_experience_min": 3, "years_experience_max": 7, "role_function": "legal", "employer_industry": null, "employer_size": null, "quality_score": 55, "travel_pct": null, "requires_shift": null, "shift_type": "unknown", "shift_type_source": null, "weekend_work": "unknown", "weekend_work_source": null, "relocation_assistance_source": null, "contractor_w2": "unknown", "required_timezone": null, "fertility_family_building_benefits_source": null, "mental_health_support_source": null, "adoption_assistance_offered_source": null, "childcare_subsidy_source": null, "learning_budget_offered_source": null, "surrogacy_assistance_offered_source": null, "cover_letter_required": null, "cover_letter_required_source": null, "assessment_required": null, "assessment_required_source": null, "application_deadline": null, "application_deadline_source": null, "visa_sponsorship": false, "us_citizenship_required": false, "security_clearance": "none", "education_required": "doctorate", "roll_up_count": null, "roll_up_total_locations": null, "explanations": [] }, { "id": "83ea4688691ead8eb6386a94bffea9c2", "title": "Associate Director, Clinical Supplies-Global Planning & Operations", "employer_name": "Summit Therapeutics", "employer_slug": "summit-therapeutics", "location_text": "Palo Alto, CA (US)", "country": "US", "employment_type": "contract", "remote_status": "unspecified", "remote_status_source": null, "remote_status_enriched_at": null, "days_in_office": null, "timezone_overlap_hours": 6, "salary_min": 175000, "salary_max": 200000, "salary_min_source": null, "salary_max_source": null, "salary_currency": "USD", "salary_type": "total_comp", "salary_type_source": null, "salary_type_enriched_at": null, "salary_period": "year", "base_salary_min": null, "base_salary_max": null, "salary_disclosed": true, "equity_included": false, "equity_included_source": null, "equity_type": [ "none" ], "k401_match": null, "match_401k_pct": null, "match_401k_pct_source": null, "k401_match_source_url": null, "k401_match_source_fields": [], "k401_contribution_source_url": null, "k401_contribution_source_fields": [], "profit_sharing": false, "bonus_offered": true, "mental_health_support": null, "childcare_subsidy": null, "fertility_family_building_benefits": null, "adoption_assistance_offered": null, "surrogacy_assistance_offered": null, "learning_budget_offered": null, "relocation_assistance": null, "top_startup_sources": [], "posted_at": "2026-05-26T12:42:57.000Z", "apply_url": "https://job-boards.greenhouse.io/summittherapeutics/jobs/4252276009", "apply_url_verified": false, "ats": "greenhouse", "url_last_checked_alive": null, "removed_at": null, "description_excerpt": "Associate Director, Clinical Supplies-Global Planning & Operations Palo Alto, CA (US) About Summit: Summit Therapeutics Inc. is a biopharmaceutical oncology company with a mission focused on improving quality of life, increasing potential duration of life, and resolving serious unmet medical needs. At Summit, we believe in building a team of world class professionals who are passionate about this mission, and it is our people who drive this mission to reality. Summit's core values include integrity, passion for excellence, purposeful urgency, collaboration, and our commitment to people. Our employees are truly the heart and soul of our culture, and they are invaluable in shaping our journey toward excellence. Summit's team is inspired to touch and help change lives through Summit's clinical studies in the field of oncology. Summit has multiple global Phase 3 clinical studies, including: Non-small Cell Lung Cancer (NSCLC) - HARMONi: Phase 3 clinical study which was intended to evaluate ivonescimab combined with chemotherapy compared to placebo plus chemotherapy in patients with EGFR-mutated, locally advanced or metastatic non-squamous NSCLC who were previously treated with a 3rd generation EGFR TKI. - HARMONi-3: Phase 3 clinical study which is intended to evaluate ivonescimab combined with chemotherapy compared to pembrolizumab combined with chemotherapy in patients with first-line metastatic NSCLC. - HARMONi-7: Phase 3 clinical study which is intended to evaluate ivonescimab monotherapy compared to pembrolizumab monotherapy in patients with first-line metastatic NSCLC. Colorectal Cancer (CRC) - HARMONi-GI3: Phase 3 clinical study intended to evaluate ivonescimab in combination with chemotherapy compared with bevacizumab", "parental_leave_weeks": null, "non_birth_parent_leave_weeks": null, "parental_leave_weeks_source": null, "non_birth_parent_leave_weeks_source": null, "parental_leave_source_url": null, "pto_days": null, "unlimited_pto": false, "sabbatical_eligible": false, "family_friendly_score": 44, "benefit_verified": false, "benefit_last_verified": null, "hire_states_allowed": [], "state_eligibility_source": null, "state_eligibility_enriched_at": null, "llm_quality_pass_at": null, "seniority": "staff_plus", "years_experience_min": 8, "years_experience_max": 12, "role_function": "marketing", "employer_industry": null, "employer_size": null, "quality_score": 55, "travel_pct": null, "requires_shift": null, "shift_type": "unknown", "shift_type_source": null, "weekend_work": "unknown", "weekend_work_source": null, "relocation_assistance_source": null, "contractor_w2": "unknown", "required_timezone": null, "fertility_family_building_benefits_source": null, "mental_health_support_source": null, "adoption_assistance_offered_source": null, "childcare_subsidy_source": null, "learning_budget_offered_source": null, "surrogacy_assistance_offered_source": null, "cover_letter_required": null, "cover_letter_required_source": null, "assessment_required": null, "assessment_required_source": null, "application_deadline": null, "application_deadline_source": null, "visa_sponsorship": false, "us_citizenship_required": false, "security_clearance": "none", "education_required": "masters", "roll_up_count": null, "roll_up_total_locations": null, "explanations": [] }, { "id": "ec000df2378537ae734fdd15cfda8eb2", "title": "Lead, Regional Medical Science Director", "employer_name": "Summit Therapeutics", "employer_slug": "summit-therapeutics", "location_text": "Raleigh, North Carolina, United States", "country": "US", "employment_type": "unknown", "remote_status": "unspecified", "remote_status_source": null, "remote_status_enriched_at": null, "days_in_office": null, "timezone_overlap_hours": 6, "salary_min": 250000, "salary_max": 270000, "salary_min_source": null, "salary_max_source": null, "salary_currency": "USD", "salary_type": "total_comp", "salary_type_source": null, "salary_type_enriched_at": null, "salary_period": "year", "base_salary_min": null, "base_salary_max": null, "salary_disclosed": true, "equity_included": false, "equity_included_source": null, "equity_type": [ "none" ], "k401_match": null, "match_401k_pct": null, "match_401k_pct_source": null, "k401_match_source_url": null, "k401_match_source_fields": [], "k401_contribution_source_url": null, "k401_contribution_source_fields": [], "profit_sharing": false, "bonus_offered": true, "mental_health_support": null, "childcare_subsidy": null, "fertility_family_building_benefits": null, "adoption_assistance_offered": null, "surrogacy_assistance_offered": null, "learning_budget_offered": null, "relocation_assistance": null, "top_startup_sources": [], "posted_at": "2026-05-22T18:15:17.000Z", "apply_url": "https://job-boards.greenhouse.io/summittherapeutics/jobs/4257505009", "apply_url_verified": false, "ats": "greenhouse", "url_last_checked_alive": null, "removed_at": null, "description_excerpt": "Lead, Regional Medical Science Director Raleigh, North Carolina, United States About Summit: Summit Therapeutics Inc. is a biopharmaceutical oncology company with a mission focused on improving quality of life, increasing potential duration of life, and resolving serious unmet medical needs. At Summit, we believe in building a team of world class professionals who are passionate about this mission, and it is our people who drive this mission to reality. Summit's core values include integrity, passion for excellence, purposeful urgency, collaboration, and our commitment to people. Our employees are truly the heart and soul of our culture, and they are invaluable in shaping our journey toward excellence. Summit's team is inspired to touch and help change lives through Summit's clinical studies in the field of oncology. Summit has multiple global Phase 3 clinical studies, including: Non-small Cell Lung Cancer (NSCLC) - HARMONi: Phase 3 clinical study which was intended to evaluate ivonescimab combined with chemotherapy compared to placebo plus chemotherapy in patients with EGFR-mutated, locally advanced or metastatic non-squamous NSCLC who were previously treated with a 3rd generation EGFR TKI. - HARMONi-3: Phase 3 clinical study which is intended to evaluate ivonescimab combined with chemotherapy compared to pembrolizumab combined with chemotherapy in patients with first-line metastatic NSCLC. - HARMONi-7: Phase 3 clinical study which is intended to evaluate ivonescimab monotherapy compared to pembrolizumab monotherapy in patients with first-line metastatic NSCLC. Colorectal Cancer (CRC) - HARMONi-GI3: Phase 3 clinical study intended to evaluate ivonescimab in combination with chemotherapy compared with bevacizumab plus", "parental_leave_weeks": null, "non_birth_parent_leave_weeks": null, "parental_leave_weeks_source": null, "non_birth_parent_leave_weeks_source": null, "parental_leave_source_url": null, "pto_days": null, "unlimited_pto": false, "sabbatical_eligible": false, "family_friendly_score": 44, "benefit_verified": false, "benefit_last_verified": null, "hire_states_allowed": [], "state_eligibility_source": null, "state_eligibility_enriched_at": null, "llm_quality_pass_at": null, "seniority": "staff_plus", "years_experience_min": 8, "years_experience_max": 12, "role_function": "data", "employer_industry": null, "employer_size": null, "quality_score": 55, "travel_pct": 75, "requires_shift": null, "shift_type": "unknown", "shift_type_source": null, "weekend_work": "unknown", "weekend_work_source": null, "relocation_assistance_source": null, "contractor_w2": "unknown", "required_timezone": null, "fertility_family_building_benefits_source": null, "mental_health_support_source": null, "adoption_assistance_offered_source": null, "childcare_subsidy_source": null, "learning_budget_offered_source": null, "surrogacy_assistance_offered_source": null, "cover_letter_required": null, "cover_letter_required_source": null, "assessment_required": null, "assessment_required_source": null, "application_deadline": null, "application_deadline_source": null, "visa_sponsorship": false, "us_citizenship_required": false, "security_clearance": "none", "education_required": "doctorate", "roll_up_count": null, "roll_up_total_locations": null, "explanations": [] }, { "id": "f9d73f579afc3220c8850eee31a09019", "title": "Senior Medical Science Liaison (TX & NM)", "employer_name": "Summit Therapeutics", "employer_slug": "summit-therapeutics", "location_text": "Dallas, Texas, United States", "country": "US", "employment_type": "unknown", "remote_status": "unspecified", "remote_status_source": null, "remote_status_enriched_at": null, "days_in_office": null, "timezone_overlap_hours": 6, "salary_min": 200000, "salary_max": 235000, "salary_min_source": null, "salary_max_source": null, "salary_currency": "USD", "salary_type": "total_comp", "salary_type_source": null, "salary_type_enriched_at": null, "salary_period": "year", "base_salary_min": null, "base_salary_max": null, "salary_disclosed": true, "equity_included": false, "equity_included_source": null, "equity_type": [ "none" ], "k401_match": null, "match_401k_pct": null, "match_401k_pct_source": null, "k401_match_source_url": null, "k401_match_source_fields": [], "k401_contribution_source_url": null, "k401_contribution_source_fields": [], "profit_sharing": false, "bonus_offered": true, "mental_health_support": null, "childcare_subsidy": null, "fertility_family_building_benefits": null, "adoption_assistance_offered": null, "surrogacy_assistance_offered": null, "learning_budget_offered": null, "relocation_assistance": null, "top_startup_sources": [], "posted_at": "2026-05-22T18:05:18.000Z", "apply_url": "https://job-boards.greenhouse.io/summittherapeutics/jobs/4256945009", "apply_url_verified": false, "ats": "greenhouse", "url_last_checked_alive": null, "removed_at": null, "description_excerpt": "Senior Medical Science Liaison (TX & NM) Dallas, Texas, United States About Summit: Summit Therapeutics Inc. is a biopharmaceutical oncology company with a mission focused on improving quality of life, increasing potential duration of life, and resolving serious unmet medical needs. At Summit, we believe in building a team of world class professionals who are passionate about this mission, and it is our people who drive this mission to reality. Summit's core values include integrity, passion for excellence, purposeful urgency, collaboration, and our commitment to people. Our employees are truly the heart and soul of our culture, and they are invaluable in shaping our journey toward excellence. Summit's team is inspired to touch and help change lives through Summit's clinical studies in the field of oncology. Summit has multiple global Phase 3 clinical studies, including: Non-small Cell Lung Cancer (NSCLC) - HARMONi: Phase 3 clinical study which was intended to evaluate ivonescimab combined with chemotherapy compared to placebo plus chemotherapy in patients with EGFR-mutated, locally advanced or metastatic non-squamous NSCLC who were previously treated with a 3rd generation EGFR TKI. - HARMONi-3: Phase 3 clinical study which is intended to evaluate ivonescimab combined with chemotherapy compared to pembrolizumab combined with chemotherapy in patients with first-line metastatic NSCLC. - HARMONi-7: Phase 3 clinical study which is intended to evaluate ivonescimab monotherapy compared to pembrolizumab monotherapy in patients with first-line metastatic NSCLC. Colorectal Cancer (CRC) - HARMONi-GI3: Phase 3 clinical study intended to evaluate ivonescimab in combination with chemotherapy compared with bevacizumab", "parental_leave_weeks": null, "non_birth_parent_leave_weeks": null, "parental_leave_weeks_source": null, "non_birth_parent_leave_weeks_source": null, "parental_leave_source_url": null, "pto_days": null, "unlimited_pto": false, "sabbatical_eligible": false, "family_friendly_score": 44, "benefit_verified": false, "benefit_last_verified": null, "hire_states_allowed": [], "state_eligibility_source": null, "state_eligibility_enriched_at": null, "llm_quality_pass_at": null, "seniority": "senior", "years_experience_min": 5, "years_experience_max": 9, "role_function": "data", "employer_industry": null, "employer_size": null, "quality_score": 55, "travel_pct": 75, "requires_shift": null, "shift_type": "unknown", "shift_type_source": null, "weekend_work": "unknown", "weekend_work_source": null, "relocation_assistance_source": null, "contractor_w2": "unknown", "required_timezone": null, "fertility_family_building_benefits_source": null, "mental_health_support_source": null, "adoption_assistance_offered_source": null, "childcare_subsidy_source": null, "learning_budget_offered_source": null, "surrogacy_assistance_offered_source": null, "cover_letter_required": null, "cover_letter_required_source": null, "assessment_required": null, "assessment_required_source": null, "application_deadline": null, "application_deadline_source": null, "visa_sponsorship": false, "us_citizenship_required": false, "security_clearance": "none", "education_required": "doctorate", "roll_up_count": null, "roll_up_total_locations": null, "explanations": [] }, { "id": "8621cb5762d9e301f4e5780f97f70677", "title": "Senior Medical Science Liaison(NY & NJ)", "employer_name": "Summit Therapeutics", "employer_slug": "summit-therapeutics", "location_text": "Brooklyn, New York, United States", "country": "US", "employment_type": "unknown", "remote_status": "unspecified", "remote_status_source": null, "remote_status_enriched_at": null, "days_in_office": null, "timezone_overlap_hours": 6, "salary_min": 200000, "salary_max": 235000, "salary_min_source": null, "salary_max_source": null, "salary_currency": "USD", "salary_type": "total_comp", "salary_type_source": null, "salary_type_enriched_at": null, "salary_period": "year", "base_salary_min": null, "base_salary_max": null, "salary_disclosed": true, "equity_included": false, "equity_included_source": null, "equity_type": [ "none" ], "k401_match": null, "match_401k_pct": null, "match_401k_pct_source": null, "k401_match_source_url": null, "k401_match_source_fields": [], "k401_contribution_source_url": null, "k401_contribution_source_fields": [], "profit_sharing": false, "bonus_offered": true, "mental_health_support": null, "childcare_subsidy": null, "fertility_family_building_benefits": null, "adoption_assistance_offered": null, "surrogacy_assistance_offered": null, "learning_budget_offered": null, "relocation_assistance": null, "top_startup_sources": [], "posted_at": "2026-05-22T18:04:48.000Z", "apply_url": "https://job-boards.greenhouse.io/summittherapeutics/jobs/4256934009", "apply_url_verified": false, "ats": "greenhouse", "url_last_checked_alive": null, "removed_at": null, "description_excerpt": "Senior Medical Science Liaison(NY & NJ) Brooklyn, New York, United States About Summit: Summit Therapeutics Inc. is a biopharmaceutical oncology company with a mission focused on improving quality of life, increasing potential duration of life, and resolving serious unmet medical needs. At Summit, we believe in building a team of world class professionals who are passionate about this mission, and it is our people who drive this mission to reality. Summit's core values include integrity, passion for excellence, purposeful urgency, collaboration, and our commitment to people. Our employees are truly the heart and soul of our culture, and they are invaluable in shaping our journey toward excellence. Summit's team is inspired to touch and help change lives through Summit's clinical studies in the field of oncology. Summit has multiple global Phase 3 clinical studies, including: Non-small Cell Lung Cancer (NSCLC) - HARMONi: Phase 3 clinical study which was intended to evaluate ivonescimab combined with chemotherapy compared to placebo plus chemotherapy in patients with EGFR-mutated, locally advanced or metastatic non-squamous NSCLC who were previously treated with a 3rd generation EGFR TKI. - HARMONi-3: Phase 3 clinical study which is intended to evaluate ivonescimab combined with chemotherapy compared to pembrolizumab combined with chemotherapy in patients with first-line metastatic NSCLC. - HARMONi-7: Phase 3 clinical study which is intended to evaluate ivonescimab monotherapy compared to pembrolizumab monotherapy in patients with first-line metastatic NSCLC. Colorectal Cancer (CRC) - HARMONi-GI3: Phase 3 clinical study intended to evaluate ivonescimab in combination with chemotherapy compared with bevacizumab", "parental_leave_weeks": null, "non_birth_parent_leave_weeks": null, "parental_leave_weeks_source": null, "non_birth_parent_leave_weeks_source": null, "parental_leave_source_url": null, "pto_days": null, "unlimited_pto": false, "sabbatical_eligible": false, "family_friendly_score": 44, "benefit_verified": false, "benefit_last_verified": null, "hire_states_allowed": [], "state_eligibility_source": null, "state_eligibility_enriched_at": null, "llm_quality_pass_at": null, "seniority": "senior", "years_experience_min": 5, "years_experience_max": 9, "role_function": "data", "employer_industry": null, "employer_size": null, "quality_score": 55, "travel_pct": 75, "requires_shift": null, "shift_type": "unknown", "shift_type_source": null, "weekend_work": "unknown", "weekend_work_source": null, "relocation_assistance_source": null, "contractor_w2": "unknown", "required_timezone": null, "fertility_family_building_benefits_source": null, "mental_health_support_source": null, "adoption_assistance_offered_source": null, "childcare_subsidy_source": null, "learning_budget_offered_source": null, "surrogacy_assistance_offered_source": null, "cover_letter_required": null, "cover_letter_required_source": null, "assessment_required": null, "assessment_required_source": null, "application_deadline": null, "application_deadline_source": null, "visa_sponsorship": false, "us_citizenship_required": false, "security_clearance": "none", "education_required": "doctorate", "roll_up_count": null, "roll_up_total_locations": null, "explanations": [] }, { "id": "7ff826bcb9c7a875630bc0f42b2c5c9b", "title": "Senior Medical Science Liaison (KS, MO, OK, AR)", "employer_name": "Summit Therapeutics", "employer_slug": "summit-therapeutics", "location_text": "Kansas City, Missouri, United States", "country": "US", "employment_type": "unknown", "remote_status": "unspecified", "remote_status_source": null, "remote_status_enriched_at": null, "days_in_office": null, "timezone_overlap_hours": 6, "salary_min": 200000, "salary_max": 235000, "salary_min_source": null, "salary_max_source": null, "salary_currency": "USD", "salary_type": "total_comp", "salary_type_source": null, "salary_type_enriched_at": null, "salary_period": "year", "base_salary_min": null, "base_salary_max": null, "salary_disclosed": true, "equity_included": false, "equity_included_source": null, "equity_type": [ "none" ], "k401_match": null, "match_401k_pct": null, "match_401k_pct_source": null, "k401_match_source_url": null, "k401_match_source_fields": [], "k401_contribution_source_url": null, "k401_contribution_source_fields": [], "profit_sharing": false, "bonus_offered": true, "mental_health_support": null, "childcare_subsidy": null, "fertility_family_building_benefits": null, "adoption_assistance_offered": null, "surrogacy_assistance_offered": null, "learning_budget_offered": null, "relocation_assistance": null, "top_startup_sources": [], "posted_at": "2026-05-22T18:03:37.000Z", "apply_url": "https://job-boards.greenhouse.io/summittherapeutics/jobs/4256943009", "apply_url_verified": false, "ats": "greenhouse", "url_last_checked_alive": null, "removed_at": null, "description_excerpt": "Senior Medical Science Liaison (KS, MO, OK, AR) Kansas City, Missouri, United States About Summit: Summit Therapeutics Inc. is a biopharmaceutical oncology company with a mission focused on improving quality of life, increasing potential duration of life, and resolving serious unmet medical needs. At Summit, we believe in building a team of world class professionals who are passionate about this mission, and it is our people who drive this mission to reality. Summit's core values include integrity, passion for excellence, purposeful urgency, collaboration, and our commitment to people. Our employees are truly the heart and soul of our culture, and they are invaluable in shaping our journey toward excellence. Summit's team is inspired to touch and help change lives through Summit's clinical studies in the field of oncology. Summit has multiple global Phase 3 clinical studies, including: Non-small Cell Lung Cancer (NSCLC) - HARMONi: Phase 3 clinical study which was intended to evaluate ivonescimab combined with chemotherapy compared to placebo plus chemotherapy in patients with EGFR-mutated, locally advanced or metastatic non-squamous NSCLC who were previously treated with a 3rd generation EGFR TKI. - HARMONi-3: Phase 3 clinical study which is intended to evaluate ivonescimab combined with chemotherapy compared to pembrolizumab combined with chemotherapy in patients with first-line metastatic NSCLC. - HARMONi-7: Phase 3 clinical study which is intended to evaluate ivonescimab monotherapy compared to pembrolizumab monotherapy in patients with first-line metastatic NSCLC. Colorectal Cancer (CRC) - HARMONi-GI3: Phase 3 clinical study intended to evaluate ivonescimab in combination with chemotherapy compared", "parental_leave_weeks": null, "non_birth_parent_leave_weeks": null, "parental_leave_weeks_source": null, "non_birth_parent_leave_weeks_source": null, "parental_leave_source_url": null, "pto_days": null, "unlimited_pto": false, "sabbatical_eligible": false, "family_friendly_score": 44, "benefit_verified": false, "benefit_last_verified": null, "hire_states_allowed": [], "state_eligibility_source": null, "state_eligibility_enriched_at": null, "llm_quality_pass_at": null, "seniority": "senior", "years_experience_min": 5, "years_experience_max": 9, "role_function": "data", "employer_industry": null, "employer_size": null, "quality_score": 55, "travel_pct": 75, "requires_shift": null, "shift_type": "unknown", "shift_type_source": null, "weekend_work": "unknown", "weekend_work_source": null, "relocation_assistance_source": null, "contractor_w2": "unknown", "required_timezone": null, "fertility_family_building_benefits_source": null, "mental_health_support_source": null, "adoption_assistance_offered_source": null, "childcare_subsidy_source": null, "learning_budget_offered_source": null, "surrogacy_assistance_offered_source": null, "cover_letter_required": null, "cover_letter_required_source": null, "assessment_required": null, "assessment_required_source": null, "application_deadline": null, "application_deadline_source": null, "visa_sponsorship": false, "us_citizenship_required": false, "security_clearance": "none", "education_required": "doctorate", "roll_up_count": null, "roll_up_total_locations": null, "explanations": [] }, { "id": "33c4239a3457666234ce1a11f2cd6ce7", "title": "Senior Director of Technical QA (GMP)", "employer_name": "Summit Therapeutics", "employer_slug": "summit-therapeutics", "location_text": "Palo Alto, CA (US)", "country": "US", "employment_type": "contract", "remote_status": "unspecified", "remote_status_source": null, "remote_status_enriched_at": null, "days_in_office": null, "timezone_overlap_hours": 6, "salary_min": 217000, "salary_max": 271000, "salary_min_source": null, "salary_max_source": null, "salary_currency": "USD", "salary_type": "total_comp", "salary_type_source": null, "salary_type_enriched_at": null, "salary_period": "year", "base_salary_min": null, "base_salary_max": null, "salary_disclosed": true, "equity_included": false, "equity_included_source": null, "equity_type": [ "none" ], "k401_match": null, "match_401k_pct": null, "match_401k_pct_source": null, "k401_match_source_url": null, "k401_match_source_fields": [], "k401_contribution_source_url": null, "k401_contribution_source_fields": [], "profit_sharing": false, "bonus_offered": true, "mental_health_support": null, "childcare_subsidy": null, "fertility_family_building_benefits": null, "adoption_assistance_offered": null, "surrogacy_assistance_offered": null, "learning_budget_offered": null, "relocation_assistance": null, "top_startup_sources": [], "posted_at": "2026-05-20T18:06:07.000Z", "apply_url": "https://job-boards.greenhouse.io/summittherapeutics/jobs/4252108009", "apply_url_verified": false, "ats": "greenhouse", "url_last_checked_alive": null, "removed_at": null, "description_excerpt": "Senior Director of Technical QA (GMP) Palo Alto, CA (US) About Summit: Summit Therapeutics Inc. is a biopharmaceutical oncology company with a mission focused on improving quality of life, increasing potential duration of life, and resolving serious unmet medical needs. At Summit, we believe in building a team of world class professionals who are passionate about this mission, and it is our people who drive this mission to reality. Summit's core values include integrity, passion for excellence, purposeful urgency, collaboration, and our commitment to people. Our employees are truly the heart and soul of our culture, and they are invaluable in shaping our journey toward excellence. Summit's team is inspired to touch and help change lives through Summit's clinical studies in the field of oncology. Summit has multiple global Phase 3 clinical studies, including: Non-small Cell Lung Cancer (NSCLC) - HARMONi: Phase 3 clinical study which was intended to evaluate ivonescimab combined with chemotherapy compared to placebo plus chemotherapy in patients with EGFR-mutated, locally advanced or metastatic non-squamous NSCLC who were previously treated with a 3rd generation EGFR TKI. - HARMONi-3: Phase 3 clinical study which is intended to evaluate ivonescimab combined with chemotherapy compared to pembrolizumab combined with chemotherapy in patients with first-line metastatic NSCLC. - HARMONi-7: Phase 3 clinical study which is intended to evaluate ivonescimab monotherapy compared to pembrolizumab monotherapy in patients with first-line metastatic NSCLC. Colorectal Cancer (CRC) - HARMONi-GI3: Phase 3 clinical study intended to evaluate ivonescimab in combination with chemotherapy compared with bevacizumab plus", "parental_leave_weeks": null, "non_birth_parent_leave_weeks": null, "parental_leave_weeks_source": null, "non_birth_parent_leave_weeks_source": null, "parental_leave_source_url": null, "pto_days": null, "unlimited_pto": false, "sabbatical_eligible": false, "family_friendly_score": 44, "benefit_verified": false, "benefit_last_verified": null, "hire_states_allowed": [], "state_eligibility_source": null, "state_eligibility_enriched_at": null, "llm_quality_pass_at": null, "seniority": "staff_plus", "years_experience_min": 8, "years_experience_max": 12, "role_function": "engineering", "employer_industry": null, "employer_size": null, "quality_score": 55, "travel_pct": null, "requires_shift": null, "shift_type": "unknown", "shift_type_source": null, "weekend_work": "unknown", "weekend_work_source": null, "relocation_assistance_source": null, "contractor_w2": "unknown", "required_timezone": null, "fertility_family_building_benefits_source": null, "mental_health_support_source": null, "adoption_assistance_offered_source": null, "childcare_subsidy_source": null, "learning_budget_offered_source": null, "surrogacy_assistance_offered_source": null, "cover_letter_required": null, "cover_letter_required_source": null, "assessment_required": null, "assessment_required_source": null, "application_deadline": null, "application_deadline_source": null, "visa_sponsorship": false, "us_citizenship_required": false, "security_clearance": "none", "education_required": "doctorate", "roll_up_count": null, "roll_up_total_locations": null, "explanations": [] }, { "id": "6f1c29981ea3e0d27f151f551ab6d1c4", "title": "Vice President, US Marketing", "employer_name": "Summit Therapeutics", "employer_slug": "summit-therapeutics", "location_text": "Princeton, NJ (US)", "country": "US", "employment_type": "unknown", "remote_status": "unspecified", "remote_status_source": null, "remote_status_enriched_at": null, "days_in_office": null, "timezone_overlap_hours": 6, "salary_min": 315000, "salary_max": 350000, "salary_min_source": null, "salary_max_source": null, "salary_currency": "USD", "salary_type": "total_comp", "salary_type_source": null, "salary_type_enriched_at": null, "salary_period": "year", "base_salary_min": null, "base_salary_max": null, "salary_disclosed": true, "equity_included": false, "equity_included_source": null, "equity_type": [ "none" ], "k401_match": null, "match_401k_pct": null, "match_401k_pct_source": null, "k401_match_source_url": null, "k401_match_source_fields": [], "k401_contribution_source_url": null, "k401_contribution_source_fields": [], "profit_sharing": false, "bonus_offered": true, "mental_health_support": null, "childcare_subsidy": null, "fertility_family_building_benefits": null, "adoption_assistance_offered": null, "surrogacy_assistance_offered": null, "learning_budget_offered": null, "relocation_assistance": null, "top_startup_sources": [], "posted_at": "2026-05-19T15:33:43.000Z", "apply_url": "https://job-boards.greenhouse.io/summittherapeutics/jobs/4252097009", "apply_url_verified": false, "ats": "greenhouse", "url_last_checked_alive": null, "removed_at": null, "description_excerpt": "Vice President, US Marketing Princeton, NJ (US) About Summit: Summit Therapeutics Inc. is a biopharmaceutical oncology company with a mission focused on improving quality of life, increasing potential duration of life, and resolving serious unmet medical needs. At Summit, we believe in building a team of world class professionals who are passionate about this mission, and it is our people who drive this mission to reality. Summit's core values include integrity, passion for excellence, purposeful urgency, collaboration, and our commitment to people. Our employees are truly the heart and soul of our culture, and they are invaluable in shaping our journey toward excellence. Summit's team is inspired to touch and help change lives through Summit's clinical studies in the field of oncology. Summit has multiple global Phase 3 clinical studies, including: Non-small Cell Lung Cancer (NSCLC) - HARMONi: Phase 3 clinical study which was intended to evaluate ivonescimab combined with chemotherapy compared to placebo plus chemotherapy in patients with EGFR-mutated, locally advanced or metastatic non-squamous NSCLC who were previously treated with a 3rd generation EGFR TKI. - HARMONi-3: Phase 3 clinical study which is intended to evaluate ivonescimab combined with chemotherapy compared to pembrolizumab combined with chemotherapy in patients with first-line metastatic NSCLC. - HARMONi-7: Phase 3 clinical study which is intended to evaluate ivonescimab monotherapy compared to pembrolizumab monotherapy in patients with first-line metastatic NSCLC. Colorectal Cancer (CRC) - HARMONi-GI3: Phase 3 clinical study intended to evaluate ivonescimab in combination with chemotherapy compared with bevacizumab plus chemotherapy. Ivonescimab is", "parental_leave_weeks": null, "non_birth_parent_leave_weeks": null, "parental_leave_weeks_source": null, "non_birth_parent_leave_weeks_source": null, "parental_leave_source_url": null, "pto_days": null, "unlimited_pto": false, "sabbatical_eligible": false, "family_friendly_score": 44, "benefit_verified": false, "benefit_last_verified": null, "hire_states_allowed": [], "state_eligibility_source": null, "state_eligibility_enriched_at": null, "llm_quality_pass_at": null, "seniority": "staff_plus", "years_experience_min": 8, "years_experience_max": 12, "role_function": "marketing", "employer_industry": null, "employer_size": null, "quality_score": 55, "travel_pct": null, "requires_shift": null, "shift_type": "unknown", "shift_type_source": null, "weekend_work": "unknown", "weekend_work_source": null, "relocation_assistance_source": null, "contractor_w2": "unknown", "required_timezone": null, "fertility_family_building_benefits_source": null, "mental_health_support_source": null, "adoption_assistance_offered_source": null, "childcare_subsidy_source": null, "learning_budget_offered_source": null, "surrogacy_assistance_offered_source": null, "cover_letter_required": null, "cover_letter_required_source": null, "assessment_required": null, "assessment_required_source": null, "application_deadline": null, "application_deadline_source": null, "visa_sponsorship": false, "us_citizenship_required": false, "security_clearance": "none", "education_required": "doctorate", "roll_up_count": null, "roll_up_total_locations": null, "explanations": [] }, { "id": "9ba5e99509fc9b81134b2dd7c0863e76", "title": "Associate Director, Regulatory CMC", "employer_name": "Summit Therapeutics", "employer_slug": "summit-therapeutics", "location_text": "Palo Alto, CA (US)", "country": "US", "employment_type": "unknown", "remote_status": "unspecified", "remote_status_source": null, "remote_status_enriched_at": null, "days_in_office": null, "timezone_overlap_hours": 6, "salary_min": 194000, "salary_max": 199000, "salary_min_source": null, "salary_max_source": null, "salary_currency": "USD", "salary_type": "total_comp", "salary_type_source": null, "salary_type_enriched_at": null, "salary_period": "year", "base_salary_min": null, "base_salary_max": null, "salary_disclosed": true, "equity_included": false, "equity_included_source": null, "equity_type": [ "none" ], "k401_match": null, "match_401k_pct": null, "match_401k_pct_source": null, "k401_match_source_url": null, "k401_match_source_fields": [], "k401_contribution_source_url": null, "k401_contribution_source_fields": [], "profit_sharing": false, "bonus_offered": true, "mental_health_support": null, "childcare_subsidy": null, "fertility_family_building_benefits": null, "adoption_assistance_offered": null, "surrogacy_assistance_offered": null, "learning_budget_offered": null, "relocation_assistance": null, "top_startup_sources": [], "posted_at": "2026-05-05T17:04:36.000Z", "apply_url": "https://job-boards.greenhouse.io/summittherapeutics/jobs/4239849009", "apply_url_verified": false, "ats": "greenhouse", "url_last_checked_alive": null, "removed_at": null, "description_excerpt": "Associate Director, Regulatory CMC Palo Alto, CA (US) About Summit: Summit Therapeutics Inc. is a biopharmaceutical oncology company with a mission focused on improving quality of life, increasing potential duration of life, and resolving serious unmet medical needs. At Summit, we believe in building a team of world class professionals who are passionate about this mission, and it is our people who drive this mission to reality. Summit's core values include integrity, passion for excellence, purposeful urgency, collaboration, and our commitment to people. Our employees are truly the heart and soul of our culture, and they are invaluable in shaping our journey toward excellence. Summit's team is inspired to touch and help change lives through Summit's clinical studies in the field of oncology. Summit has multiple global Phase 3 clinical studies, including: Non-small Cell Lung Cancer (NSCLC) - HARMONi: Phase 3 clinical study which was intended to evaluate ivonescimab combined with chemotherapy compared to placebo plus chemotherapy in patients with EGFR-mutated, locally advanced or metastatic non-squamous NSCLC who were previously treated with a 3rd generation EGFR TKI. - HARMONi-3: Phase 3 clinical study which is intended to evaluate ivonescimab combined with chemotherapy compared to pembrolizumab combined with chemotherapy in patients with first-line metastatic NSCLC. - HARMONi-7: Phase 3 clinical study which is intended to evaluate ivonescimab monotherapy compared to pembrolizumab monotherapy in patients with first-line metastatic NSCLC. Colorectal Cancer (CRC) - HARMONi-GI3: Phase 3 clinical study intended to evaluate ivonescimab in combination with chemotherapy compared with bevacizumab plus chemotherapy. Ivonescimab", "parental_leave_weeks": null, "non_birth_parent_leave_weeks": null, "parental_leave_weeks_source": null, "non_birth_parent_leave_weeks_source": null, "parental_leave_source_url": null, "pto_days": null, "unlimited_pto": false, "sabbatical_eligible": false, "family_friendly_score": 44, "benefit_verified": false, "benefit_last_verified": null, "hire_states_allowed": [], "state_eligibility_source": null, "state_eligibility_enriched_at": null, "llm_quality_pass_at": null, "seniority": "staff_plus", "years_experience_min": 8, "years_experience_max": 12, "role_function": "other", "employer_industry": null, "employer_size": null, "quality_score": 55, "travel_pct": null, "requires_shift": null, "shift_type": "unknown", "shift_type_source": null, "weekend_work": "unknown", "weekend_work_source": null, "relocation_assistance_source": null, "contractor_w2": "unknown", "required_timezone": null, "fertility_family_building_benefits_source": null, "mental_health_support_source": null, "adoption_assistance_offered_source": null, "childcare_subsidy_source": null, "learning_budget_offered_source": null, "surrogacy_assistance_offered_source": null, "cover_letter_required": null, "cover_letter_required_source": null, "assessment_required": null, "assessment_required_source": null, "application_deadline": null, "application_deadline_source": null, "visa_sponsorship": false, "us_citizenship_required": false, "security_clearance": "none", "education_required": "masters", "roll_up_count": null, "roll_up_total_locations": null, "explanations": [] }, { "id": "92b30f39d60a1211e9c1a3ef9b5f4f1b", "title": "Senior Principal Engineer/Associate Director, Drug Product MSAT", "employer_name": "Summit Therapeutics", "employer_slug": "summit-therapeutics", "location_text": "Princeton, NJ", "country": "US", "employment_type": "unknown", "remote_status": "unspecified", "remote_status_source": null, "remote_status_enriched_at": null, "days_in_office": null, "timezone_overlap_hours": 6, "salary_min": 180000, "salary_max": 195000, "salary_min_source": null, "salary_max_source": null, "salary_currency": "USD", "salary_type": "total_comp", "salary_type_source": null, "salary_type_enriched_at": null, "salary_period": "year", "base_salary_min": null, "base_salary_max": null, "salary_disclosed": true, "equity_included": false, "equity_included_source": null, "equity_type": [ "none" ], "k401_match": null, "match_401k_pct": null, "match_401k_pct_source": null, "k401_match_source_url": null, "k401_match_source_fields": [], "k401_contribution_source_url": null, "k401_contribution_source_fields": [], "profit_sharing": false, "bonus_offered": true, "mental_health_support": null, "childcare_subsidy": null, "fertility_family_building_benefits": null, "adoption_assistance_offered": null, "surrogacy_assistance_offered": null, "learning_budget_offered": null, "relocation_assistance": null, "top_startup_sources": [], "posted_at": "2026-04-27T22:34:29.000Z", "apply_url": "https://job-boards.greenhouse.io/summittherapeutics/jobs/4232801009", "apply_url_verified": false, "ats": "greenhouse", "url_last_checked_alive": null, "removed_at": null, "description_excerpt": "Senior Principal Engineer/Associate Director, Drug Product MSAT Princeton, NJ About Summit: Summit Therapeutics Inc. is a biopharmaceutical oncology company with a mission focused on improving quality of life, increasing potential duration of life, and resolving serious unmet medical needs. At Summit, we believe in building a team of world class professionals who are passionate about this mission, and it is our people who drive this mission to reality. Summit's core values include integrity, passion for excellence, purposeful urgency, collaboration, and our commitment to people. Our employees are truly the heart and soul of our culture, and they are invaluable in shaping our journey toward excellence. Summit's team is inspired to touch and help change lives through Summit's clinical studies in the field of oncology. Summit has multiple global Phase 3 clinical studies, including: Non-small Cell Lung Cancer (NSCLC) - HARMONi: Phase 3 clinical study which was intended to evaluate ivonescimab combined with chemotherapy compared to placebo plus chemotherapy in patients with EGFR-mutated, locally advanced or metastatic non-squamous NSCLC who were previously treated with a 3rd generation EGFR TKI. - HARMONi-3: Phase 3 clinical study which is intended to evaluate ivonescimab combined with chemotherapy compared to pembrolizumab combined with chemotherapy in patients with first-line metastatic NSCLC. - HARMONi-7: Phase 3 clinical study which is intended to evaluate ivonescimab monotherapy compared to pembrolizumab monotherapy in patients with first-line metastatic NSCLC. Colorectal Cancer (CRC) - HARMONi-GI3: Phase 3 clinical study intended to evaluate ivonescimab in combination with chemotherapy compared with bevacizumab plus chemotherapy.", "parental_leave_weeks": null, "non_birth_parent_leave_weeks": null, "parental_leave_weeks_source": null, "non_birth_parent_leave_weeks_source": null, "parental_leave_source_url": null, "pto_days": null, "unlimited_pto": false, "sabbatical_eligible": false, "family_friendly_score": 44, "benefit_verified": false, "benefit_last_verified": null, "hire_states_allowed": [], "state_eligibility_source": null, "state_eligibility_enriched_at": null, "llm_quality_pass_at": null, "seniority": "staff_plus", "years_experience_min": 10, "years_experience_max": null, "role_function": "engineering", "employer_industry": null, "employer_size": null, "quality_score": 55, "travel_pct": null, "requires_shift": null, "shift_type": "unknown", "shift_type_source": null, "weekend_work": "unknown", "weekend_work_source": null, "relocation_assistance_source": null, "contractor_w2": "unknown", "required_timezone": null, "fertility_family_building_benefits_source": null, "mental_health_support_source": null, "adoption_assistance_offered_source": null, "childcare_subsidy_source": null, "learning_budget_offered_source": null, "surrogacy_assistance_offered_source": null, "cover_letter_required": null, "cover_letter_required_source": null, "assessment_required": null, "assessment_required_source": null, "application_deadline": null, "application_deadline_source": null, "visa_sponsorship": false, "us_citizenship_required": false, "security_clearance": "none", "education_required": "doctorate", "roll_up_count": null, "roll_up_total_locations": null, "explanations": [] }, { "id": "02497b5e5a2bb55acc3d8fb1714a3a4a", "title": "Senior Manager, Clinical Site Partner (Germany)", "employer_name": "Summit Therapeutics", "employer_slug": "summit-therapeutics", "location_text": "Remote-Field (Germany)", "country": "DE", "employment_type": "contract", "remote_status": "remote", "remote_status_source": null, "remote_status_enriched_at": null, "days_in_office": 0, "timezone_overlap_hours": 3, "salary_min": null, "salary_max": null, "salary_min_source": null, "salary_max_source": null, "salary_currency": "UNSPECIFIED", "salary_type": "base", "salary_type_source": null, "salary_type_enriched_at": null, "salary_period": null, "base_salary_min": null, "base_salary_max": null, "salary_disclosed": false, "equity_included": false, "equity_included_source": null, "equity_type": [ "none" ], "k401_match": null, "match_401k_pct": null, "match_401k_pct_source": null, "k401_match_source_url": null, "k401_match_source_fields": [], "k401_contribution_source_url": null, "k401_contribution_source_fields": [], "profit_sharing": false, "bonus_offered": true, "mental_health_support": null, "childcare_subsidy": null, "fertility_family_building_benefits": null, "adoption_assistance_offered": null, "surrogacy_assistance_offered": null, "learning_budget_offered": null, "relocation_assistance": null, "top_startup_sources": [], "posted_at": "2026-04-24T16:29:09.000Z", "apply_url": "https://job-boards.greenhouse.io/summittherapeutics/jobs/4229849009", "apply_url_verified": false, "ats": "greenhouse", "url_last_checked_alive": null, "removed_at": null, "description_excerpt": "Senior Manager, Clinical Site Partner (Germany) Remote-Field (Germany) About Summit: Summit Therapeutics Inc. is a biopharmaceutical oncology company with a mission focused on improving quality of life, increasing potential duration of life, and resolving serious unmet medical needs. At Summit, we believe in building a team of world class professionals who are passionate about this mission, and it is our people who drive this mission to reality. Summit's core values include integrity, passion for excellence, purposeful urgency, collaboration, and our commitment to people. Our employees are truly the heart and soul of our culture, and they are invaluable in shaping our journey toward excellence. Summit's team is inspired to touch and help change lives through Summit's clinical studies in the field of oncology. Summit has multiple global Phase 3 clinical studies, including: Non-small Cell Lung Cancer (NSCLC) - HARMONi: Phase 3 clinical study which was intended to evaluate ivonescimab combined with chemotherapy compared to placebo plus chemotherapy in patients with EGFR-mutated, locally advanced or metastatic non-squamous NSCLC who were previously treated with a 3rd generation EGFR TKI. - HARMONi-3: Phase 3 clinical study which is intended to evaluate ivonescimab combined with chemotherapy compared to pembrolizumab combined with chemotherapy in patients with first-line metastatic NSCLC. - HARMONi-7: Phase 3 clinical study which is intended to evaluate ivonescimab monotherapy compared to pembrolizumab monotherapy in patients with first-line metastatic NSCLC. Colorectal Cancer (CRC) - HARMONi-GI3: Phase 3 clinical study intended to evaluate ivonescimab in combination with chemotherapy compared with bevacizumab plus chemotherapy. Ivonescimab", "parental_leave_weeks": null, "non_birth_parent_leave_weeks": null, "parental_leave_weeks_source": null, "non_birth_parent_leave_weeks_source": null, "parental_leave_source_url": null, "pto_days": null, "unlimited_pto": false, "sabbatical_eligible": false, "family_friendly_score": 48, "benefit_verified": false, "benefit_last_verified": null, "hire_states_allowed": [], "state_eligibility_source": null, "state_eligibility_enriched_at": null, "llm_quality_pass_at": null, "seniority": "senior", "years_experience_min": 5, "years_experience_max": 9, "role_function": "marketing", "employer_industry": null, "employer_size": null, "quality_score": 45, "travel_pct": 75, "requires_shift": null, "shift_type": "unknown", "shift_type_source": null, "weekend_work": "unknown", "weekend_work_source": null, "relocation_assistance_source": null, "contractor_w2": "contractor", "required_timezone": null, "fertility_family_building_benefits_source": null, "mental_health_support_source": null, "adoption_assistance_offered_source": null, "childcare_subsidy_source": null, "learning_budget_offered_source": null, "surrogacy_assistance_offered_source": null, "cover_letter_required": null, "cover_letter_required_source": null, "assessment_required": null, "assessment_required_source": null, "application_deadline": null, "application_deadline_source": null, "visa_sponsorship": false, "us_citizenship_required": false, "security_clearance": "none", "education_required": "doctorate", "roll_up_count": null, "roll_up_total_locations": null, "explanations": [] }, { "id": "c852f69b15998cda8de0a20cd61a3d2d", "title": "Executive Director, US Market Access Strategy", "employer_name": "Summit Therapeutics", "employer_slug": "summit-therapeutics", "location_text": "Princeton, NJ", "country": "US", "employment_type": "unknown", "remote_status": "unspecified", "remote_status_source": null, "remote_status_enriched_at": null, "days_in_office": null, "timezone_overlap_hours": 6, "salary_min": 245000, "salary_max": 307000, "salary_min_source": null, "salary_max_source": null, "salary_currency": "USD", "salary_type": "total_comp", "salary_type_source": null, "salary_type_enriched_at": null, "salary_period": "year", "base_salary_min": null, "base_salary_max": null, "salary_disclosed": true, "equity_included": false, "equity_included_source": null, "equity_type": [ "none" ], "k401_match": null, "match_401k_pct": null, "match_401k_pct_source": null, "k401_match_source_url": null, "k401_match_source_fields": [], "k401_contribution_source_url": null, "k401_contribution_source_fields": [], "profit_sharing": false, "bonus_offered": true, "mental_health_support": null, "childcare_subsidy": null, "fertility_family_building_benefits": null, "adoption_assistance_offered": null, "surrogacy_assistance_offered": null, "learning_budget_offered": null, "relocation_assistance": null, "top_startup_sources": [], "posted_at": "2026-04-17T21:04:08.000Z", "apply_url": "https://job-boards.greenhouse.io/summittherapeutics/jobs/4224815009", "apply_url_verified": false, "ats": "greenhouse", "url_last_checked_alive": null, "removed_at": null, "description_excerpt": "Executive Director, US Market Access Strategy Princeton, NJ About Summit: Summit Therapeutics Inc. is a biopharmaceutical oncology company with a mission focused on improving quality of life, increasing potential duration of life, and resolving serious unmet medical needs. At Summit, we believe in building a team of world class professionals who are passionate about this mission, and it is our people who drive this mission to reality. Summit's core values include integrity, passion for excellence, purposeful urgency, collaboration, and our commitment to people. Our employees are truly the heart and soul of our culture, and they are invaluable in shaping our journey toward excellence. Summit's team is inspired to touch and help change lives through Summit's clinical studies in the field of oncology. Summit has multiple global Phase 3 clinical studies, including: Non-small Cell Lung Cancer (NSCLC) - HARMONi: Phase 3 clinical study which was intended to evaluate ivonescimab combined with chemotherapy compared to placebo plus chemotherapy in patients with EGFR-mutated, locally advanced or metastatic non-squamous NSCLC who were previously treated with a 3rd generation EGFR TKI. - HARMONi-3: Phase 3 clinical study which is intended to evaluate ivonescimab combined with chemotherapy compared to pembrolizumab combined with chemotherapy in patients with first-line metastatic NSCLC. - HARMONi-7: Phase 3 clinical study which is intended to evaluate ivonescimab monotherapy compared to pembrolizumab monotherapy in patients with first-line metastatic NSCLC. Colorectal Cancer (CRC) - HARMONi-GI3: Phase 3 clinical study intended to evaluate ivonescimab in combination with chemotherapy compared with bevacizumab plus chemotherapy. Ivonescimab", "parental_leave_weeks": null, "non_birth_parent_leave_weeks": null, "parental_leave_weeks_source": null, "non_birth_parent_leave_weeks_source": null, "parental_leave_source_url": null, "pto_days": null, "unlimited_pto": false, "sabbatical_eligible": false, "family_friendly_score": 44, "benefit_verified": false, "benefit_last_verified": null, "hire_states_allowed": [], "state_eligibility_source": null, "state_eligibility_enriched_at": null, "llm_quality_pass_at": null, "seniority": "staff_plus", "years_experience_min": 8, "years_experience_max": 12, "role_function": "marketing", "employer_industry": null, "employer_size": null, "quality_score": 55, "travel_pct": null, "requires_shift": null, "shift_type": "unknown", "shift_type_source": null, "weekend_work": "unknown", "weekend_work_source": null, "relocation_assistance_source": null, "contractor_w2": "unknown", "required_timezone": null, "fertility_family_building_benefits_source": null, "mental_health_support_source": null, "adoption_assistance_offered_source": null, "childcare_subsidy_source": null, "learning_budget_offered_source": null, "surrogacy_assistance_offered_source": null, "cover_letter_required": null, "cover_letter_required_source": null, "assessment_required": null, "assessment_required_source": null, "application_deadline": null, "application_deadline_source": null, "visa_sponsorship": false, "us_citizenship_required": false, "security_clearance": "none", "education_required": "bachelors", "roll_up_count": null, "roll_up_total_locations": null, "explanations": [] }, { "id": "a5a523946a4e2415e144cde98e54ddcb", "title": "Clinical Trial Manager", "employer_name": "Summit Therapeutics", "employer_slug": "summit-therapeutics", "location_text": "Palo Alto, CA (US)", "country": "US", "employment_type": "unknown", "remote_status": "unspecified", "remote_status_source": null, "remote_status_enriched_at": null, "days_in_office": null, "timezone_overlap_hours": 6, "salary_min": 140000, "salary_max": 150000, "salary_min_source": null, "salary_max_source": null, "salary_currency": "USD", "salary_type": "total_comp", "salary_type_source": null, "salary_type_enriched_at": null, "salary_period": "year", "base_salary_min": null, "base_salary_max": null, "salary_disclosed": true, "equity_included": false, "equity_included_source": null, "equity_type": [ "none" ], "k401_match": null, "match_401k_pct": null, "match_401k_pct_source": null, "k401_match_source_url": null, "k401_match_source_fields": [], "k401_contribution_source_url": null, "k401_contribution_source_fields": [], "profit_sharing": false, "bonus_offered": true, "mental_health_support": null, "childcare_subsidy": null, "fertility_family_building_benefits": null, "adoption_assistance_offered": null, "surrogacy_assistance_offered": null, "learning_budget_offered": null, "relocation_assistance": null, "top_startup_sources": [], "posted_at": "2026-04-16T14:57:06.000Z", "apply_url": "https://job-boards.greenhouse.io/summittherapeutics/jobs/4223217009", "apply_url_verified": false, "ats": "greenhouse", "url_last_checked_alive": null, "removed_at": null, "description_excerpt": "Clinical Trial Manager Palo Alto, CA (US) About Summit: Summit Therapeutics Inc. is a biopharmaceutical oncology company with a mission focused on improving quality of life, increasing potential duration of life, and resolving serious unmet medical needs. At Summit, we believe in building a team of world class professionals who are passionate about this mission, and it is our people who drive this mission to reality. Summit's core values include integrity, passion for excellence, purposeful urgency, collaboration, and our commitment to people. Our employees are truly the heart and soul of our culture, and they are invaluable in shaping our journey toward excellence. Summit's team is inspired to touch and help change lives through Summit's clinical studies in the field of oncology. Summit has multiple global Phase 3 clinical studies, including: Non-small Cell Lung Cancer (NSCLC) - HARMONi: Phase 3 clinical study which was intended to evaluate ivonescimab combined with chemotherapy compared to placebo plus chemotherapy in patients with EGFR-mutated, locally advanced or metastatic non-squamous NSCLC who were previously treated with a 3rd generation EGFR TKI. - HARMONi-3: Phase 3 clinical study which is intended to evaluate ivonescimab combined with chemotherapy compared to pembrolizumab combined with chemotherapy in patients with first-line metastatic NSCLC. - HARMONi-7: Phase 3 clinical study which is intended to evaluate ivonescimab monotherapy compared to pembrolizumab monotherapy in patients with first-line metastatic NSCLC. Colorectal Cancer (CRC) - HARMONi-GI3: Phase 3 clinical study intended to evaluate ivonescimab in combination with chemotherapy compared with bevacizumab plus chemotherapy. Ivonescimab is", "parental_leave_weeks": null, "non_birth_parent_leave_weeks": null, "parental_leave_weeks_source": null, "non_birth_parent_leave_weeks_source": null, "parental_leave_source_url": null, "pto_days": null, "unlimited_pto": false, "sabbatical_eligible": false, "family_friendly_score": 44, "benefit_verified": false, "benefit_last_verified": null, "hire_states_allowed": [], "state_eligibility_source": null, "state_eligibility_enriched_at": null, "llm_quality_pass_at": null, "seniority": "senior", "years_experience_min": 5, "years_experience_max": 9, "role_function": "healthcare", "employer_industry": null, "employer_size": null, "quality_score": 55, "travel_pct": 20, "requires_shift": null, "shift_type": "unknown", "shift_type_source": null, "weekend_work": "unknown", "weekend_work_source": null, "relocation_assistance_source": null, "contractor_w2": "unknown", "required_timezone": null, "fertility_family_building_benefits_source": null, "mental_health_support_source": null, "adoption_assistance_offered_source": null, "childcare_subsidy_source": null, "learning_budget_offered_source": null, "surrogacy_assistance_offered_source": null, "cover_letter_required": null, "cover_letter_required_source": null, "assessment_required": null, "assessment_required_source": null, "application_deadline": null, "application_deadline_source": null, "visa_sponsorship": false, "us_citizenship_required": false, "security_clearance": "none", "education_required": "bachelors", "roll_up_count": null, "roll_up_total_locations": null, "explanations": [] }, { "id": "7cbdee5465fce8046ccba9bfe43af374", "title": "Clinical Supplies Manager", "employer_name": "Summit Therapeutics", "employer_slug": "summit-therapeutics", "location_text": "Remote", "country": "unknown", "employment_type": "contract", "remote_status": "remote", "remote_status_source": null, "remote_status_enriched_at": null, "days_in_office": 0, "timezone_overlap_hours": 3, "salary_min": 120000, "salary_max": 145000, "salary_min_source": null, "salary_max_source": null, "salary_currency": "USD", "salary_type": "total_comp", "salary_type_source": null, "salary_type_enriched_at": null, "salary_period": "year", "base_salary_min": null, "base_salary_max": null, "salary_disclosed": true, "equity_included": false, "equity_included_source": null, "equity_type": [ "none" ], "k401_match": null, "match_401k_pct": null, "match_401k_pct_source": null, "k401_match_source_url": null, "k401_match_source_fields": [], "k401_contribution_source_url": null, "k401_contribution_source_fields": [], "profit_sharing": false, "bonus_offered": true, "mental_health_support": null, "childcare_subsidy": null, "fertility_family_building_benefits": null, "adoption_assistance_offered": null, "surrogacy_assistance_offered": null, "learning_budget_offered": null, "relocation_assistance": null, "top_startup_sources": [], "posted_at": "2026-04-01T16:11:31.000Z", "apply_url": "https://job-boards.greenhouse.io/summittherapeutics/jobs/4205206009", "apply_url_verified": false, "ats": "greenhouse", "url_last_checked_alive": null, "removed_at": null, "description_excerpt": "Clinical Supplies Manager Remote About Summit: Summit Therapeutics Inc. is a biopharmaceutical oncology company with a mission focused on improving quality of life, increasing potential duration of life, and resolving serious unmet medical needs. At Summit, we believe in building a team of world class professionals who are passionate about this mission, and it is our people who drive this mission to reality. Summit's core values include integrity, passion for excellence, purposeful urgency, collaboration, and our commitment to people. Our employees are truly the heart and soul of our culture, and they are invaluable in shaping our journey toward excellence. Summit's team is inspired to touch and help change lives through Summit's clinical studies in the field of oncology. Summit has multiple global Phase 3 clinical studies, including: Non-small Cell Lung Cancer (NSCLC) - HARMONi: Phase 3 clinical study which was intended to evaluate ivonescimab combined with chemotherapy compared to placebo plus chemotherapy in patients with EGFR-mutated, locally advanced or metastatic non-squamous NSCLC who were previously treated with a 3rd generation EGFR TKI. - HARMONi-3: Phase 3 clinical study which is intended to evaluate ivonescimab combined with chemotherapy compared to pembrolizumab combined with chemotherapy in patients with first-line metastatic NSCLC. - HARMONi-7: Phase 3 clinical study which is intended to evaluate ivonescimab monotherapy compared to pembrolizumab monotherapy in patients with first-line metastatic NSCLC. Colorectal Cancer (CRC) - HARMONi-GI3: Phase 3 clinical study intended to evaluate ivonescimab in combination with chemotherapy compared with bevacizumab plus chemotherapy. Ivonescimab is an investigational therapy", "parental_leave_weeks": null, "non_birth_parent_leave_weeks": null, "parental_leave_weeks_source": null, "non_birth_parent_leave_weeks_source": null, "parental_leave_source_url": null, "pto_days": null, "unlimited_pto": false, "sabbatical_eligible": false, "family_friendly_score": 52, "benefit_verified": false, "benefit_last_verified": null, "hire_states_allowed": [], "state_eligibility_source": null, "state_eligibility_enriched_at": null, "llm_quality_pass_at": null, "seniority": "senior", "years_experience_min": 5, "years_experience_max": 9, "role_function": "healthcare", "employer_industry": null, "employer_size": null, "quality_score": 55, "travel_pct": null, "requires_shift": null, "shift_type": "unknown", "shift_type_source": null, "weekend_work": "unknown", "weekend_work_source": null, "relocation_assistance_source": null, "contractor_w2": "unknown", "required_timezone": null, "fertility_family_building_benefits_source": null, "mental_health_support_source": null, "adoption_assistance_offered_source": null, "childcare_subsidy_source": null, "learning_budget_offered_source": null, "surrogacy_assistance_offered_source": null, "cover_letter_required": null, "cover_letter_required_source": null, "assessment_required": null, "assessment_required_source": null, "application_deadline": null, "application_deadline_source": null, "visa_sponsorship": false, "us_citizenship_required": false, "security_clearance": "none", "education_required": "bachelors", "roll_up_count": null, "roll_up_total_locations": null, "explanations": [] }, { "id": "bfa2708e8b6b8e3e2025cee93aa43216", "title": "Director, Biostatistics", "employer_name": "Summit Therapeutics", "employer_slug": "summit-therapeutics", "location_text": "Palo Alto, California, United States", "country": "US", "employment_type": "unknown", "remote_status": "unspecified", "remote_status_source": null, "remote_status_enriched_at": null, "days_in_office": null, "timezone_overlap_hours": 6, "salary_min": 203000, "salary_max": 253000, "salary_min_source": null, "salary_max_source": null, "salary_currency": "USD", "salary_type": "total_comp", "salary_type_source": null, "salary_type_enriched_at": null, "salary_period": "year", "base_salary_min": null, "base_salary_max": null, "salary_disclosed": true, "equity_included": false, "equity_included_source": null, "equity_type": [ "none" ], "k401_match": null, "match_401k_pct": null, "match_401k_pct_source": null, "k401_match_source_url": null, "k401_match_source_fields": [], "k401_contribution_source_url": null, "k401_contribution_source_fields": [], "profit_sharing": false, "bonus_offered": true, "mental_health_support": null, "childcare_subsidy": null, "fertility_family_building_benefits": null, "adoption_assistance_offered": null, "surrogacy_assistance_offered": null, "learning_budget_offered": null, "relocation_assistance": null, "top_startup_sources": [], "posted_at": "2026-03-18T13:22:19.000Z", "apply_url": "https://job-boards.greenhouse.io/summittherapeutics/jobs/4183442009", "apply_url_verified": false, "ats": "greenhouse", "url_last_checked_alive": null, "removed_at": null, "description_excerpt": "Director, Biostatistics Palo Alto, California, United States About Summit: Summit Therapeutics Inc. is a biopharmaceutical oncology company with a mission focused on improving quality of life, increasing potential duration of life, and resolving serious unmet medical needs. At Summit, we believe in building a team of world class professionals who are passionate about this mission, and it is our people who drive this mission to reality. Summit's core values include integrity, passion for excellence, purposeful urgency, collaboration, and our commitment to people. Our employees are truly the heart and soul of our culture, and they are invaluable in shaping our journey toward excellence. Summit's team is inspired to touch and help change lives through Summit's clinical studies in the field of oncology. Summit has multiple global Phase 3 clinical studies, including: Non-small Cell Lung Cancer (NSCLC) - HARMONi: Phase 3 clinical study which was intended to evaluate ivonescimab combined with chemotherapy compared to placebo plus chemotherapy in patients with EGFR-mutated, locally advanced or metastatic non-squamous NSCLC who were previously treated with a 3rd generation EGFR TKI. - HARMONi-3: Phase 3 clinical study which is intended to evaluate ivonescimab combined with chemotherapy compared to pembrolizumab combined with chemotherapy in patients with first-line metastatic NSCLC. - HARMONi-7: Phase 3 clinical study which is intended to evaluate ivonescimab monotherapy compared to pembrolizumab monotherapy in patients with first-line metastatic NSCLC. Colorectal Cancer (CRC) - HARMONi-GI3: Phase 3 clinical study intended to evaluate ivonescimab in combination with chemotherapy compared with bevacizumab plus chemotherapy. Ivonescimab is", "parental_leave_weeks": null, "non_birth_parent_leave_weeks": null, "parental_leave_weeks_source": null, "non_birth_parent_leave_weeks_source": null, "parental_leave_source_url": null, "pto_days": null, "unlimited_pto": false, "sabbatical_eligible": false, "family_friendly_score": 44, "benefit_verified": false, "benefit_last_verified": null, "hire_states_allowed": [], "state_eligibility_source": null, "state_eligibility_enriched_at": null, "llm_quality_pass_at": null, "seniority": "staff_plus", "years_experience_min": 8, "years_experience_max": null, "role_function": "other", "employer_industry": null, "employer_size": null, "quality_score": 55, "travel_pct": null, "requires_shift": null, "shift_type": "unknown", "shift_type_source": null, "weekend_work": "unknown", "weekend_work_source": null, "relocation_assistance_source": null, "contractor_w2": "unknown", "required_timezone": null, "fertility_family_building_benefits_source": null, "mental_health_support_source": null, "adoption_assistance_offered_source": null, "childcare_subsidy_source": null, "learning_budget_offered_source": null, "surrogacy_assistance_offered_source": null, "cover_letter_required": null, "cover_letter_required_source": null, "assessment_required": null, "assessment_required_source": null, "application_deadline": null, "application_deadline_source": null, "visa_sponsorship": false, "us_citizenship_required": false, "security_clearance": "none", "education_required": "doctorate", "roll_up_count": null, "roll_up_total_locations": null, "explanations": [] }, { "id": "c04896ded1230a6e85e309b45b7dd1d1", "title": "Sr. Commercial Attorney, Transactions", "employer_name": "Summit Therapeutics", "employer_slug": "summit-therapeutics", "location_text": "Remote (US)", "country": "US", "employment_type": "contract", "remote_status": "remote", "remote_status_source": null, "remote_status_enriched_at": null, "days_in_office": 0, "timezone_overlap_hours": 6, "salary_min": 217000, "salary_max": 271000, "salary_min_source": null, "salary_max_source": null, "salary_currency": "USD", "salary_type": "total_comp", "salary_type_source": null, "salary_type_enriched_at": null, "salary_period": "year", "base_salary_min": null, "base_salary_max": null, "salary_disclosed": true, "equity_included": false, "equity_included_source": null, "equity_type": [ "none" ], "k401_match": null, "match_401k_pct": null, "match_401k_pct_source": null, "k401_match_source_url": null, "k401_match_source_fields": [], "k401_contribution_source_url": null, "k401_contribution_source_fields": [], "profit_sharing": false, "bonus_offered": true, "mental_health_support": null, "childcare_subsidy": null, "fertility_family_building_benefits": null, "adoption_assistance_offered": null, "surrogacy_assistance_offered": null, "learning_budget_offered": null, "relocation_assistance": null, "top_startup_sources": [], "posted_at": "2026-03-09T16:03:38.000Z", "apply_url": "https://job-boards.greenhouse.io/summittherapeutics/jobs/4174612009", "apply_url_verified": false, "ats": "greenhouse", "url_last_checked_alive": null, "removed_at": null, "description_excerpt": "Sr. Commercial Attorney, Transactions Remote (US) About Summit: Summit Therapeutics Inc. is a biopharmaceutical oncology company with a mission focused on improving quality of life, increasing potential duration of life, and resolving serious unmet medical needs. At Summit, we believe in building a team of world class professionals who are passionate about this mission, and it is our people who drive this mission to reality. Summit's core values include integrity, passion for excellence, purposeful urgency, collaboration, and our commitment to people. Our employees are truly the heart and soul of our culture, and they are invaluable in shaping our journey toward excellence. Summit's team is inspired to touch and help change lives through Summit's clinical studies in the field of oncology. Summit has multiple global Phase 3 clinical studies, including: Non-small Cell Lung Cancer (NSCLC) - HARMONi: Phase 3 clinical study which was intended to evaluate ivonescimab combined with chemotherapy compared to placebo plus chemotherapy in patients with EGFR-mutated, locally advanced or metastatic non-squamous NSCLC who were previously treated with a 3rd generation EGFR TKI. - HARMONi-3: Phase 3 clinical study which is intended to evaluate ivonescimab combined with chemotherapy compared to pembrolizumab combined with chemotherapy in patients with first-line metastatic NSCLC. - HARMONi-7: Phase 3 clinical study which is intended to evaluate ivonescimab monotherapy compared to pembrolizumab monotherapy in patients with first-line metastatic NSCLC. Colorectal Cancer (CRC) - HARMONi-GI3: Phase 3 clinical study intended to evaluate ivonescimab in combination with chemotherapy compared with bevacizumab plus chemotherapy. Ivonescimab is an", "parental_leave_weeks": null, "non_birth_parent_leave_weeks": null, "parental_leave_weeks_source": null, "non_birth_parent_leave_weeks_source": null, "parental_leave_source_url": null, "pto_days": null, "unlimited_pto": false, "sabbatical_eligible": false, "family_friendly_score": 52, "benefit_verified": false, "benefit_last_verified": null, "hire_states_allowed": [], "state_eligibility_source": null, "state_eligibility_enriched_at": null, "llm_quality_pass_at": null, "seniority": "senior", "years_experience_min": 5, "years_experience_max": 9, "role_function": "legal", "employer_industry": null, "employer_size": null, "quality_score": 55, "travel_pct": null, "requires_shift": null, "shift_type": "unknown", "shift_type_source": null, "weekend_work": "unknown", "weekend_work_source": null, "relocation_assistance_source": null, "contractor_w2": "unknown", "required_timezone": null, "fertility_family_building_benefits_source": null, "mental_health_support_source": null, "adoption_assistance_offered_source": null, "childcare_subsidy_source": null, "learning_budget_offered_source": null, "surrogacy_assistance_offered_source": null, "cover_letter_required": null, "cover_letter_required_source": null, "assessment_required": null, "assessment_required_source": null, "application_deadline": null, "application_deadline_source": null, "visa_sponsorship": false, "us_citizenship_required": false, "security_clearance": "none", "education_required": "doctorate", "roll_up_count": null, "roll_up_total_locations": null, "explanations": [] }, { "id": "2869277bda3611afc254947606e36bbe", "title": "Senior Medical Science Liaison (ND, SD, MN, IA, MO, NE)", "employer_name": "Summit Therapeutics", "employer_slug": "summit-therapeutics", "location_text": "Remote-Field (US)", "country": "US", "employment_type": "unknown", "remote_status": "remote", "remote_status_source": null, "remote_status_enriched_at": null, "days_in_office": 0, "timezone_overlap_hours": 6, "salary_min": 200000, "salary_max": 235000, "salary_min_source": null, "salary_max_source": null, "salary_currency": "USD", "salary_type": "total_comp", "salary_type_source": null, "salary_type_enriched_at": null, "salary_period": "year", "base_salary_min": null, "base_salary_max": null, "salary_disclosed": true, "equity_included": false, "equity_included_source": null, "equity_type": [ "none" ], "k401_match": null, "match_401k_pct": null, "match_401k_pct_source": null, "k401_match_source_url": null, "k401_match_source_fields": [], "k401_contribution_source_url": null, "k401_contribution_source_fields": [], "profit_sharing": false, "bonus_offered": true, "mental_health_support": null, "childcare_subsidy": null, "fertility_family_building_benefits": null, "adoption_assistance_offered": null, "surrogacy_assistance_offered": null, "learning_budget_offered": null, "relocation_assistance": null, "top_startup_sources": [], "posted_at": "2026-03-09T16:03:35.000Z", "apply_url": "https://job-boards.greenhouse.io/summittherapeutics/jobs/4174514009", "apply_url_verified": false, "ats": "greenhouse", "url_last_checked_alive": null, "removed_at": null, "description_excerpt": "Senior Medical Science Liaison (ND, SD, MN, IA, MO, NE) Remote-Field (US) About Summit: Summit Therapeutics Inc. is a biopharmaceutical oncology company with a mission focused on improving quality of life, increasing potential duration of life, and resolving serious unmet medical needs. At Summit, we believe in building a team of world class professionals who are passionate about this mission, and it is our people who drive this mission to reality. Summit's core values include integrity, passion for excellence, purposeful urgency, collaboration, and our commitment to people. Our employees are truly the heart and soul of our culture, and they are invaluable in shaping our journey toward excellence. Summit's team is inspired to touch and help change lives through Summit's clinical studies in the field of oncology. Summit has multiple global Phase 3 clinical studies, including: Non-small Cell Lung Cancer (NSCLC) - HARMONi: Phase 3 clinical study which was intended to evaluate ivonescimab combined with chemotherapy compared to placebo plus chemotherapy in patients with EGFR-mutated, locally advanced or metastatic non-squamous NSCLC who were previously treated with a 3rd generation EGFR TKI. - HARMONi-3: Phase 3 clinical study which is intended to evaluate ivonescimab combined with chemotherapy compared to pembrolizumab combined with chemotherapy in patients with first-line metastatic NSCLC. - HARMONi-7: Phase 3 clinical study which is intended to evaluate ivonescimab monotherapy compared to pembrolizumab monotherapy in patients with first-line metastatic NSCLC. Colorectal Cancer (CRC) - HARMONi-GI3: Phase 3 clinical study intended to evaluate ivonescimab in combination with chemotherapy compared with", "parental_leave_weeks": null, "non_birth_parent_leave_weeks": null, "parental_leave_weeks_source": null, "non_birth_parent_leave_weeks_source": null, "parental_leave_source_url": null, "pto_days": null, "unlimited_pto": false, "sabbatical_eligible": false, "family_friendly_score": 52, "benefit_verified": false, "benefit_last_verified": null, "hire_states_allowed": [], "state_eligibility_source": null, "state_eligibility_enriched_at": null, "llm_quality_pass_at": null, "seniority": "senior", "years_experience_min": 5, "years_experience_max": 9, "role_function": "data", "employer_industry": null, "employer_size": null, "quality_score": 55, "travel_pct": 75, "requires_shift": null, "shift_type": "unknown", "shift_type_source": null, "weekend_work": "unknown", "weekend_work_source": null, "relocation_assistance_source": null, "contractor_w2": "unknown", "required_timezone": null, "fertility_family_building_benefits_source": null, "mental_health_support_source": null, "adoption_assistance_offered_source": null, "childcare_subsidy_source": null, "learning_budget_offered_source": null, "surrogacy_assistance_offered_source": null, "cover_letter_required": null, "cover_letter_required_source": null, "assessment_required": null, "assessment_required_source": null, "application_deadline": null, "application_deadline_source": null, "visa_sponsorship": false, "us_citizenship_required": false, "security_clearance": "none", "education_required": "doctorate", "roll_up_count": null, "roll_up_total_locations": null, "explanations": [] }, { "id": "22229cd190f37ae8fb872d79488ab713", "title": "Senior Manager, Regulatory Affairs", "employer_name": "Summit Therapeutics", "employer_slug": "summit-therapeutics", "location_text": "Oxford (UK)", "country": "GB", "employment_type": "unknown", "remote_status": "unspecified", "remote_status_source": null, "remote_status_enriched_at": null, "days_in_office": null, "timezone_overlap_hours": 3, "salary_min": null, "salary_max": null, "salary_min_source": null, "salary_max_source": null, "salary_currency": "EUR", "salary_type": "base", "salary_type_source": null, "salary_type_enriched_at": null, "salary_period": null, "base_salary_min": null, "base_salary_max": null, "salary_disclosed": false, "equity_included": false, "equity_included_source": null, "equity_type": [ "none" ], "k401_match": null, "match_401k_pct": null, "match_401k_pct_source": null, "k401_match_source_url": null, "k401_match_source_fields": [], "k401_contribution_source_url": null, "k401_contribution_source_fields": [], "profit_sharing": false, "bonus_offered": true, "mental_health_support": null, "childcare_subsidy": null, "fertility_family_building_benefits": null, "adoption_assistance_offered": null, "surrogacy_assistance_offered": null, "learning_budget_offered": null, "relocation_assistance": null, "top_startup_sources": [], "posted_at": "2026-03-09T16:03:32.000Z", "apply_url": "https://job-boards.greenhouse.io/summittherapeutics/jobs/4174479009", "apply_url_verified": false, "ats": "greenhouse", "url_last_checked_alive": null, "removed_at": null, "description_excerpt": "Senior Manager, Regulatory Affairs Oxford (UK) About Summit: Summit Therapeutics Inc. is a biopharmaceutical oncology company with a mission focused on improving quality of life, increasing potential duration of life, and resolving serious unmet medical needs. At Summit, we believe in building a team of world class professionals who are passionate about this mission, and it is our people who drive this mission to reality. Summit's core values include integrity, passion for excellence, purposeful urgency, collaboration, and our commitment to people. Our employees are truly the heart and soul of our culture, and they are invaluable in shaping our journey toward excellence. Summit's team is inspired to touch and help change lives through Summit's clinical studies in the field of oncology. Summit has multiple global Phase 3 clinical studies, including: Non-small Cell Lung Cancer (NSCLC) - HARMONi: Phase 3 clinical study which was intended to evaluate ivonescimab combined with chemotherapy compared to placebo plus chemotherapy in patients with EGFR-mutated, locally advanced or metastatic non-squamous NSCLC who were previously treated with a 3rd generation EGFR TKI. - HARMONi-3: Phase 3 clinical study which is intended to evaluate ivonescimab combined with chemotherapy compared to pembrolizumab combined with chemotherapy in patients with first-line metastatic NSCLC. - HARMONi-7: Phase 3 clinical study which is intended to evaluate ivonescimab monotherapy compared to pembrolizumab monotherapy in patients with first-line metastatic NSCLC. Colorectal Cancer (CRC) - HARMONi-GI3: Phase 3 clinical study intended to evaluate ivonescimab in combination with chemotherapy compared with bevacizumab plus chemotherapy. Ivonescimab is an", "parental_leave_weeks": null, "non_birth_parent_leave_weeks": null, "parental_leave_weeks_source": null, "non_birth_parent_leave_weeks_source": null, "parental_leave_source_url": null, "pto_days": null, "unlimited_pto": false, "sabbatical_eligible": false, "family_friendly_score": 40, "benefit_verified": false, "benefit_last_verified": null, "hire_states_allowed": [], "state_eligibility_source": null, "state_eligibility_enriched_at": null, "llm_quality_pass_at": null, "seniority": "senior", "years_experience_min": 3, "years_experience_max": 7, "role_function": "other", "employer_industry": null, "employer_size": null, "quality_score": 45, "travel_pct": null, "requires_shift": null, "shift_type": "unknown", "shift_type_source": null, "weekend_work": "unknown", "weekend_work_source": null, "relocation_assistance_source": null, "contractor_w2": "unknown", "required_timezone": null, "fertility_family_building_benefits_source": null, "mental_health_support_source": null, "adoption_assistance_offered_source": null, "childcare_subsidy_source": null, "learning_budget_offered_source": null, "surrogacy_assistance_offered_source": null, "cover_letter_required": null, "cover_letter_required_source": null, "assessment_required": null, "assessment_required_source": null, "application_deadline": null, "application_deadline_source": null, "visa_sponsorship": false, "us_citizenship_required": false, "security_clearance": "none", "education_required": "doctorate", "roll_up_count": null, "roll_up_total_locations": null, "explanations": [] }, { "id": "8e2f32c3935761abab11d36da5dcdc4d", "title": "Senior Director, Sales Operations (Oncology)", "employer_name": "Summit Therapeutics", "employer_slug": "summit-therapeutics", "location_text": "Princeton, NJ (US)", "country": "US", "employment_type": "unknown", "remote_status": "unspecified", "remote_status_source": null, "remote_status_enriched_at": null, "days_in_office": null, "timezone_overlap_hours": 6, "salary_min": 231000, "salary_max": 285000, "salary_min_source": null, "salary_max_source": null, "salary_currency": "USD", "salary_type": "total_comp", "salary_type_source": null, "salary_type_enriched_at": null, "salary_period": "year", "base_salary_min": null, "base_salary_max": null, "salary_disclosed": true, "equity_included": true, "equity_included_source": null, "equity_type": [ "options" ], "k401_match": null, "match_401k_pct": null, "match_401k_pct_source": null, "k401_match_source_url": null, "k401_match_source_fields": [], "k401_contribution_source_url": null, "k401_contribution_source_fields": [], "profit_sharing": false, "bonus_offered": true, "mental_health_support": null, "childcare_subsidy": null, "fertility_family_building_benefits": null, "adoption_assistance_offered": null, "surrogacy_assistance_offered": null, "learning_budget_offered": null, "relocation_assistance": null, "top_startup_sources": [], "posted_at": "2026-03-09T16:03:18.000Z", "apply_url": "https://job-boards.greenhouse.io/summittherapeutics/jobs/4174529009", "apply_url_verified": false, "ats": "greenhouse", "url_last_checked_alive": null, "removed_at": null, "description_excerpt": "Senior Director, Sales Operations (Oncology) Princeton, NJ (US) About Summit: Summit Therapeutics Inc. is a biopharmaceutical oncology company with a mission focused on improving quality of life, increasing potential duration of life, and resolving serious unmet medical needs. At Summit, we believe in building a team of world class professionals who are passionate about this mission, and it is our people who drive this mission to reality. Summit's core values include integrity, passion for excellence, purposeful urgency, collaboration, and our commitment to people. Our employees are truly the heart and soul of our culture, and they are invaluable in shaping our journey toward excellence. Summit's team is inspired to touch and help change lives through Summit's clinical studies in the field of oncology. Summit has multiple global Phase 3 clinical studies, including: Non-small Cell Lung Cancer (NSCLC) - HARMONi: Phase 3 clinical study which was intended to evaluate ivonescimab combined with chemotherapy compared to placebo plus chemotherapy in patients with EGFR-mutated, locally advanced or metastatic non-squamous NSCLC who were previously treated with a 3rd generation EGFR TKI. - HARMONi-3: Phase 3 clinical study which is intended to evaluate ivonescimab combined with chemotherapy compared to pembrolizumab combined with chemotherapy in patients with first-line metastatic NSCLC. - HARMONi-7: Phase 3 clinical study which is intended to evaluate ivonescimab monotherapy compared to pembrolizumab monotherapy in patients with first-line metastatic NSCLC. Colorectal Cancer (CRC) - HARMONi-GI3: Phase 3 clinical study intended to evaluate ivonescimab in combination with chemotherapy compared with bevacizumab plus chemotherapy. Ivonescimab", "parental_leave_weeks": null, "non_birth_parent_leave_weeks": null, "parental_leave_weeks_source": null, "non_birth_parent_leave_weeks_source": null, "parental_leave_source_url": null, "pto_days": null, "unlimited_pto": false, "sabbatical_eligible": false, "family_friendly_score": 44, "benefit_verified": false, "benefit_last_verified": null, "hire_states_allowed": [], "state_eligibility_source": null, "state_eligibility_enriched_at": null, "llm_quality_pass_at": null, "seniority": "staff_plus", "years_experience_min": 8, "years_experience_max": 12, "role_function": "sales", "employer_industry": null, "employer_size": null, "quality_score": 55, "travel_pct": null, "requires_shift": null, "shift_type": "unknown", "shift_type_source": null, "weekend_work": "unknown", "weekend_work_source": null, "relocation_assistance_source": null, "contractor_w2": "unknown", "required_timezone": null, "fertility_family_building_benefits_source": null, "mental_health_support_source": null, "adoption_assistance_offered_source": null, "childcare_subsidy_source": null, "learning_budget_offered_source": null, "surrogacy_assistance_offered_source": null, "cover_letter_required": null, "cover_letter_required_source": null, "assessment_required": null, "assessment_required_source": null, "application_deadline": null, "application_deadline_source": null, "visa_sponsorship": false, "us_citizenship_required": false, "security_clearance": "none", "education_required": "masters", "roll_up_count": null, "roll_up_total_locations": null, "explanations": [] }, { "id": "5630ab7e43cf3af968a402fa4929a65e", "title": "Director, Safety Physician", "employer_name": "Summit Therapeutics", "employer_slug": "summit-therapeutics", "location_text": "Remote (UK)", "country": "GB", "employment_type": "unknown", "remote_status": "remote", "remote_status_source": null, "remote_status_enriched_at": null, "days_in_office": 0, "timezone_overlap_hours": 3, "salary_min": null, "salary_max": null, "salary_min_source": null, "salary_max_source": null, "salary_currency": "USD", "salary_type": "base", "salary_type_source": null, "salary_type_enriched_at": null, "salary_period": null, "base_salary_min": null, "base_salary_max": null, "salary_disclosed": false, "equity_included": false, "equity_included_source": null, "equity_type": [ "none" ], "k401_match": null, "match_401k_pct": null, "match_401k_pct_source": null, "k401_match_source_url": null, "k401_match_source_fields": [], "k401_contribution_source_url": null, "k401_contribution_source_fields": [], "profit_sharing": false, "bonus_offered": true, "mental_health_support": null, "childcare_subsidy": null, "fertility_family_building_benefits": null, "adoption_assistance_offered": null, "surrogacy_assistance_offered": null, "learning_budget_offered": null, "relocation_assistance": null, "top_startup_sources": [], "posted_at": "2026-03-09T16:02:42.000Z", "apply_url": "https://job-boards.greenhouse.io/summittherapeutics/jobs/4174771009", "apply_url_verified": false, "ats": "greenhouse", "url_last_checked_alive": null, "removed_at": null, "description_excerpt": "Director, Safety Physician Remote (UK) About Summit: Summit Therapeutics Inc. is a biopharmaceutical oncology company with a mission focused on improving quality of life, increasing potential duration of life, and resolving serious unmet medical needs. At Summit, we believe in building a team of world class professionals who are passionate about this mission, and it is our people who drive this mission to reality. Summit's core values include integrity, passion for excellence, purposeful urgency, collaboration, and our commitment to people. Our employees are truly the heart and soul of our culture, and they are invaluable in shaping our journey toward excellence. Summit's team is inspired to touch and help change lives through Summit's clinical studies in the field of oncology. Summit has multiple global Phase 3 clinical studies, including: Non-small Cell Lung Cancer (NSCLC) - HARMONi: Phase 3 clinical study which was intended to evaluate ivonescimab combined with chemotherapy compared to placebo plus chemotherapy in patients with EGFR-mutated, locally advanced or metastatic non-squamous NSCLC who were previously treated with a 3rd generation EGFR TKI. - HARMONi-3: Phase 3 clinical study which is intended to evaluate ivonescimab combined with chemotherapy compared to pembrolizumab combined with chemotherapy in patients with first-line metastatic NSCLC. - HARMONi-7: Phase 3 clinical study which is intended to evaluate ivonescimab monotherapy compared to pembrolizumab monotherapy in patients with first-line metastatic NSCLC. Colorectal Cancer (CRC) - HARMONi-GI3: Phase 3 clinical study intended to evaluate ivonescimab in combination with chemotherapy compared with bevacizumab plus chemotherapy. Ivonescimab is an investigational", "parental_leave_weeks": null, "non_birth_parent_leave_weeks": null, "parental_leave_weeks_source": null, "non_birth_parent_leave_weeks_source": null, "parental_leave_source_url": null, "pto_days": null, "unlimited_pto": false, "sabbatical_eligible": false, "family_friendly_score": 48, "benefit_verified": false, "benefit_last_verified": null, "hire_states_allowed": [], "state_eligibility_source": null, "state_eligibility_enriched_at": null, "llm_quality_pass_at": null, "seniority": "staff_plus", "years_experience_min": 8, "years_experience_max": 12, "role_function": "data", "employer_industry": null, "employer_size": null, "quality_score": 45, "travel_pct": null, "requires_shift": null, "shift_type": "unknown", "shift_type_source": null, "weekend_work": "unknown", "weekend_work_source": null, "relocation_assistance_source": null, "contractor_w2": "unknown", "required_timezone": null, "fertility_family_building_benefits_source": null, "mental_health_support_source": null, "adoption_assistance_offered_source": null, "childcare_subsidy_source": null, "learning_budget_offered_source": null, "surrogacy_assistance_offered_source": null, "cover_letter_required": null, "cover_letter_required_source": null, "assessment_required": null, "assessment_required_source": null, "application_deadline": null, "application_deadline_source": null, "visa_sponsorship": false, "us_citizenship_required": false, "security_clearance": "none", "education_required": "none", "roll_up_count": null, "roll_up_total_locations": null, "explanations": [] }, { "id": "34217c08575a6538238bad0835e9e308", "title": "Director, Clinical Scientist", "employer_name": "Summit Therapeutics", "employer_slug": "summit-therapeutics", "location_text": "Princeton, NJ (US)", "country": "US", "employment_type": "unknown", "remote_status": "unspecified", "remote_status_source": null, "remote_status_enriched_at": null, "days_in_office": null, "timezone_overlap_hours": 6, "salary_min": 200000, "salary_max": 250000, "salary_min_source": null, "salary_max_source": null, "salary_currency": "USD", "salary_type": "total_comp", "salary_type_source": null, "salary_type_enriched_at": null, "salary_period": "year", "base_salary_min": null, "base_salary_max": null, "salary_disclosed": true, "equity_included": false, "equity_included_source": null, "equity_type": [ "none" ], "k401_match": null, "match_401k_pct": null, "match_401k_pct_source": null, "k401_match_source_url": null, "k401_match_source_fields": [], "k401_contribution_source_url": null, "k401_contribution_source_fields": [], "profit_sharing": false, "bonus_offered": true, "mental_health_support": null, "childcare_subsidy": null, "fertility_family_building_benefits": null, "adoption_assistance_offered": null, "surrogacy_assistance_offered": null, "learning_budget_offered": null, "relocation_assistance": null, "top_startup_sources": [], "posted_at": "2026-03-09T16:02:35.000Z", "apply_url": "https://job-boards.greenhouse.io/summittherapeutics/jobs/4174773009", "apply_url_verified": false, "ats": "greenhouse", "url_last_checked_alive": null, "removed_at": null, "description_excerpt": "Director, Clinical Scientist Princeton, NJ (US) About Summit: Summit Therapeutics Inc. is a biopharmaceutical oncology company with a mission focused on improving quality of life, increasing potential duration of life, and resolving serious unmet medical needs. At Summit, we believe in building a team of world class professionals who are passionate about this mission, and it is our people who drive this mission to reality. Summit's core values include integrity, passion for excellence, purposeful urgency, collaboration, and our commitment to people. Our employees are truly the heart and soul of our culture, and they are invaluable in shaping our journey toward excellence. Summit's team is inspired to touch and help change lives through Summit's clinical studies in the field of oncology. Summit has multiple global Phase 3 clinical studies, including: Non-small Cell Lung Cancer (NSCLC) - HARMONi: Phase 3 clinical study which was intended to evaluate ivonescimab combined with chemotherapy compared to placebo plus chemotherapy in patients with EGFR-mutated, locally advanced or metastatic non-squamous NSCLC who were previously treated with a 3rd generation EGFR TKI. - HARMONi-3: Phase 3 clinical study which is intended to evaluate ivonescimab combined with chemotherapy compared to pembrolizumab combined with chemotherapy in patients with first-line metastatic NSCLC. - HARMONi-7: Phase 3 clinical study which is intended to evaluate ivonescimab monotherapy compared to pembrolizumab monotherapy in patients with first-line metastatic NSCLC. Colorectal Cancer (CRC) - HARMONi-GI3: Phase 3 clinical study intended to evaluate ivonescimab in combination with chemotherapy compared with bevacizumab plus chemotherapy. Ivonescimab is an", "parental_leave_weeks": null, "non_birth_parent_leave_weeks": null, "parental_leave_weeks_source": null, "non_birth_parent_leave_weeks_source": null, "parental_leave_source_url": null, "pto_days": null, "unlimited_pto": false, "sabbatical_eligible": false, "family_friendly_score": 44, "benefit_verified": false, "benefit_last_verified": null, "hire_states_allowed": [], "state_eligibility_source": null, "state_eligibility_enriched_at": null, "llm_quality_pass_at": null, "seniority": "staff_plus", "years_experience_min": 8, "years_experience_max": 12, "role_function": "data", "employer_industry": null, "employer_size": null, "quality_score": 55, "travel_pct": null, "requires_shift": null, "shift_type": "unknown", "shift_type_source": null, "weekend_work": "unknown", "weekend_work_source": null, "relocation_assistance_source": null, "contractor_w2": "unknown", "required_timezone": null, "fertility_family_building_benefits_source": null, "mental_health_support_source": null, "adoption_assistance_offered_source": null, "childcare_subsidy_source": null, "learning_budget_offered_source": null, "surrogacy_assistance_offered_source": null, "cover_letter_required": null, "cover_letter_required_source": null, "assessment_required": null, "assessment_required_source": null, "application_deadline": null, "application_deadline_source": null, "visa_sponsorship": false, "us_citizenship_required": false, "security_clearance": "none", "education_required": "doctorate", "roll_up_count": null, "roll_up_total_locations": null, "explanations": [] }, { "id": "a79dbfc0c871c37da8dc7173b9ec1dc7", "title": "Associate Director, Biostatistics", "employer_name": "Summit Therapeutics", "employer_slug": "summit-therapeutics", "location_text": "Palo Alto, California, United States", "country": "US", "employment_type": "unknown", "remote_status": "unspecified", "remote_status_source": null, "remote_status_enriched_at": null, "days_in_office": null, "timezone_overlap_hours": 6, "salary_min": 190000, "salary_max": 210000, "salary_min_source": null, "salary_max_source": null, "salary_currency": "USD", "salary_type": "total_comp", "salary_type_source": null, "salary_type_enriched_at": null, "salary_period": "year", "base_salary_min": null, "base_salary_max": null, "salary_disclosed": true, "equity_included": false, "equity_included_source": null, "equity_type": [ "none" ], "k401_match": null, "match_401k_pct": null, "match_401k_pct_source": null, "k401_match_source_url": null, "k401_match_source_fields": [], "k401_contribution_source_url": null, "k401_contribution_source_fields": [], "profit_sharing": false, "bonus_offered": true, "mental_health_support": null, "childcare_subsidy": null, "fertility_family_building_benefits": null, "adoption_assistance_offered": null, "surrogacy_assistance_offered": null, "learning_budget_offered": null, "relocation_assistance": null, "top_startup_sources": [], "posted_at": "2026-03-09T15:59:07.000Z", "apply_url": "https://job-boards.greenhouse.io/summittherapeutics/jobs/4174817009", "apply_url_verified": false, "ats": "greenhouse", "url_last_checked_alive": null, "removed_at": null, "description_excerpt": "Associate Director, Biostatistics Palo Alto, California, United States About Summit: Summit Therapeutics Inc. is a biopharmaceutical oncology company with a mission focused on improving quality of life, increasing potential duration of life, and resolving serious unmet medical needs. At Summit, we believe in building a team of world class professionals who are passionate about this mission, and it is our people who drive this mission to reality. Summit's core values include integrity, passion for excellence, purposeful urgency, collaboration, and our commitment to people. Our employees are truly the heart and soul of our culture, and they are invaluable in shaping our journey toward excellence. Summit's team is inspired to touch and help change lives through Summit's clinical studies in the field of oncology. Summit has multiple global Phase 3 clinical studies, including: Non-small Cell Lung Cancer (NSCLC) - HARMONi: Phase 3 clinical study which was intended to evaluate ivonescimab combined with chemotherapy compared to placebo plus chemotherapy in patients with EGFR-mutated, locally advanced or metastatic non-squamous NSCLC who were previously treated with a 3rd generation EGFR TKI. - HARMONi-3: Phase 3 clinical study which is intended to evaluate ivonescimab combined with chemotherapy compared to pembrolizumab combined with chemotherapy in patients with first-line metastatic NSCLC. - HARMONi-7: Phase 3 clinical study which is intended to evaluate ivonescimab monotherapy compared to pembrolizumab monotherapy in patients with first-line metastatic NSCLC. Colorectal Cancer (CRC) - HARMONi-GI3: Phase 3 clinical study intended to evaluate ivonescimab in combination with chemotherapy compared with bevacizumab plus chemotherapy. Ivonescimab", "parental_leave_weeks": null, "non_birth_parent_leave_weeks": null, "parental_leave_weeks_source": null, "non_birth_parent_leave_weeks_source": null, "parental_leave_source_url": null, "pto_days": null, "unlimited_pto": false, "sabbatical_eligible": false, "family_friendly_score": 44, "benefit_verified": false, "benefit_last_verified": null, "hire_states_allowed": [], "state_eligibility_source": null, "state_eligibility_enriched_at": null, "llm_quality_pass_at": null, "seniority": "staff_plus", "years_experience_min": 8, "years_experience_max": 12, "role_function": "other", "employer_industry": null, "employer_size": null, "quality_score": 55, "travel_pct": null, "requires_shift": null, "shift_type": "unknown", "shift_type_source": null, "weekend_work": "unknown", "weekend_work_source": null, "relocation_assistance_source": null, "contractor_w2": "unknown", "required_timezone": null, "fertility_family_building_benefits_source": null, "mental_health_support_source": null, "adoption_assistance_offered_source": null, "childcare_subsidy_source": null, "learning_budget_offered_source": null, "surrogacy_assistance_offered_source": null, "cover_letter_required": null, "cover_letter_required_source": null, "assessment_required": null, "assessment_required_source": null, "application_deadline": null, "application_deadline_source": null, "visa_sponsorship": false, "us_citizenship_required": false, "security_clearance": "none", "education_required": "doctorate", "roll_up_count": null, "roll_up_total_locations": null, "explanations": [] } ], "json_ld": [ { "@context": "https://schema.org", "@type": "Organization", "name": "Summit Therapeutics", "url": "https://fewerjobs.com/employers/summit-therapeutics", "sameAs": [] }, { "@context": "https://schema.org", "@type": "ItemList", "name": "Summit Therapeutics open jobs", "itemListElement": [ { "@type": "ListItem", "position": 1, "url": "https://fewerjobs.com/jobs/summit-therapeutics/executive-director-regulatory-affairs-global-regulatory-leader-81a77d2f", "item": { "@context": "https://schema.org", "@type": "JobPosting", "title": "Executive Director, Regulatory Affairs – Global Regulatory Leader", "description": "

Executive Director, Regulatory Affairs – Global Regulatory Leader at Summit Therapeutics - (Remote US) - Executive Director, Regulatory Affairs – Global Regulatory Leader (Remote US) About Summit: Summit Therapeutics Inc. is a biopharmaceutical oncology company with a mission focused on improving quality of life, increasing potential duration of life, and resolving serious unmet medical needs. At Summit, we believe in building a team of world class professionals who are passionate about this mission, and it is our people who drive this mission to reality. Summit's core values include integrity, passion for excellence, purposeful urgency, collaboration, and our commitment to people. Our employees are truly the heart and soul of our culture, and they are invaluable in shaping our journey toward excellence. Summit's team is inspired to touch and help change lives through Summit's clinical studies in the field of oncology. Summit has multiple global Phase 3 clinical studies, including: Non-small Cell Lung Cancer (NSCLC) - HARMONi: Phase 3 clinical study which was intended to evaluate ivonescimab combined with chemotherapy compared to placebo plus chemotherapy in patients with EGFR-mutated, locally advanced or metastatic non-squamous NSCLC who were previously treated with a 3rd generation EGFR TKI. - HARMONi-3: Phase 3 clinical study which is intended to evaluate ivonescimab combined with chemotherapy compared to pembrolizumab combined with chemotherapy in patients with first-line metastatic NSCLC. - HARMONi-7: Phase 3 clinical study which is intended to evaluate ivonescimab monotherapy compared to pembrolizumab monotherapy in patients with first-line metastatic NSCLC. Colorectal Cancer (CRC) - HARMONi-GI3: Phase 3 clinical study intended to evaluate ivonescimab in combination with chemotherapy compared with bevacizumab plus

", "datePosted": "2026-06-05T14:46:04.000Z", "employmentType": "OTHER", "identifier": { "@type": "PropertyValue", "name": "Summit Therapeutics", "value": "81a77d2f703c8a734b1f4152e2061b4b" }, "hiringOrganization": { "@type": "Organization", "name": "Summit Therapeutics" }, "jobLocationType": "TELECOMMUTE", "applicantLocationRequirements": { "@type": "Country", "name": "USA" }, "estimatedSalary": { "@type": "MonetaryAmount", "currency": "USD", "value": { "@type": "QuantitativeValue", "minValue": 231000, "maxValue": 285000, "unitText": "YEAR" }, "description": "Total compensation" }, "directApply": false, "incentiveCompensation": "Bonus", "experienceRequirements": { "@type": "OccupationalExperienceRequirements", "monthsOfExperience": 180 }, "educationRequirements": "Doctorate", "url": "https://fewerjobs.com/jobs/summit-therapeutics/executive-director-regulatory-affairs-global-regulatory-leader-81a77d2f" } }, { "@type": "ListItem", "position": 2, "url": "https://fewerjobs.com/jobs/summit-therapeutics/director-portfolio-strategy-4c10bf45", "item": { "@context": "https://schema.org", "@type": "JobPosting", "title": "Director, Portfolio Strategy", "description": "

Director, Portfolio Strategy at Summit Therapeutics - Palo Alto, CA (US) - Director, Portfolio Strategy Palo Alto, CA (US) About Summit: Summit Therapeutics Inc. is a biopharmaceutical oncology company with a mission focused on improving quality of life, increasing potential duration of life, and resolving serious unmet medical needs. At Summit, we believe in building a team of world class professionals who are passionate about this mission, and it is our people who drive this mission to reality. Summit's core values include integrity, passion for excellence, purposeful urgency, collaboration, and our commitment to people. Our employees are truly the heart and soul of our culture, and they are invaluable in shaping our journey toward excellence. Summit's team is inspired to touch and help change lives through Summit's clinical studies in the field of oncology. Summit has multiple global Phase 3 clinical studies, including: Non-small Cell Lung Cancer (NSCLC) - HARMONi: Phase 3 clinical study which was intended to evaluate ivonescimab combined with chemotherapy compared to placebo plus chemotherapy in patients with EGFR-mutated, locally advanced or metastatic non-squamous NSCLC who were previously treated with a 3rd generation EGFR TKI. - HARMONi-3: Phase 3 clinical study which is intended to evaluate ivonescimab combined with chemotherapy compared to pembrolizumab combined with chemotherapy in patients with first-line metastatic NSCLC. - HARMONi-7: Phase 3 clinical study which is intended to evaluate ivonescimab monotherapy compared to pembrolizumab monotherapy in patients with first-line metastatic NSCLC. Colorectal Cancer (CRC) - HARMONi-GI3: Phase 3 clinical study intended to evaluate ivonescimab in combination with chemotherapy compared with bevacizumab plus chemotherapy. Ivonescimab is

", "datePosted": "2026-06-05T13:19:12.000Z", "employmentType": "OTHER", "identifier": { "@type": "PropertyValue", "name": "Summit Therapeutics", "value": "4c10bf45a7eb963ac29116b93548a466" }, "hiringOrganization": { "@type": "Organization", "name": "Summit Therapeutics" }, "jobLocation": { "@type": "Place", "address": { "@type": "PostalAddress", "addressCountry": "US", "addressLocality": "Palo Alto" } }, "estimatedSalary": { "@type": "MonetaryAmount", "currency": "USD", "value": { "@type": "QuantitativeValue", "minValue": 200000, "maxValue": 250000, "unitText": "YEAR" }, "description": "Total compensation" }, "directApply": false, "incentiveCompensation": "Bonus", "experienceRequirements": { "@type": "OccupationalExperienceRequirements", "monthsOfExperience": 96 }, "educationRequirements": "Doctorate", "url": "https://fewerjobs.com/jobs/summit-therapeutics/director-portfolio-strategy-4c10bf45" } }, { "@type": "ListItem", "position": 3, "url": "https://fewerjobs.com/jobs/summit-therapeutics/corporate-counsel-clinical-contracts-ecb97733", "item": { "@context": "https://schema.org", "@type": "JobPosting", "title": "Corporate Counsel, Clinical Contracts", "description": "

Corporate Counsel, Clinical Contracts at Summit Therapeutics - Remote (US) - Corporate Counsel, Clinical Contracts Remote (US) About Summit: Summit Therapeutics Inc. is a biopharmaceutical oncology company with a mission focused on improving quality of life, increasing potential duration of life, and resolving serious unmet medical needs. At Summit, we believe in building a team of world class professionals who are passionate about this mission, and it is our people who drive this mission to reality. Summit's core values include integrity, passion for excellence, purposeful urgency, collaboration, and our commitment to people. Our employees are truly the heart and soul of our culture, and they are invaluable in shaping our journey toward excellence. Summit's team is inspired to touch and help change lives through Summit's clinical studies in the field of oncology. Summit has multiple global Phase 3 clinical studies, including: Non-small Cell Lung Cancer (NSCLC) - HARMONi: Phase 3 clinical study which was intended to evaluate ivonescimab combined with chemotherapy compared to placebo plus chemotherapy in patients with EGFR-mutated, locally advanced or metastatic non-squamous NSCLC who were previously treated with a 3rd generation EGFR TKI. - HARMONi-3: Phase 3 clinical study which is intended to evaluate ivonescimab combined with chemotherapy compared to pembrolizumab combined with chemotherapy in patients with first-line metastatic NSCLC. - HARMONi-7: Phase 3 clinical study which is intended to evaluate ivonescimab monotherapy compared to pembrolizumab monotherapy in patients with first-line metastatic NSCLC. Colorectal Cancer (CRC) - HARMONi-GI3: Phase 3 clinical study intended to evaluate ivonescimab in combination with chemotherapy compared with bevacizumab plus chemotherapy. Ivonescimab is an

", "datePosted": "2026-05-27T15:38:56.000Z", "employmentType": "CONTRACTOR", "identifier": { "@type": "PropertyValue", "name": "Summit Therapeutics", "value": "ecb977336ca320c11a19901b2063e5ee" }, "hiringOrganization": { "@type": "Organization", "name": "Summit Therapeutics" }, "jobLocationType": "TELECOMMUTE", "applicantLocationRequirements": { "@type": "Country", "name": "USA" }, "estimatedSalary": { "@type": "MonetaryAmount", "currency": "USD", "value": { "@type": "QuantitativeValue", "minValue": 158000, "maxValue": 185000, "unitText": "YEAR" }, "description": "Total compensation" }, "directApply": false, "incentiveCompensation": "Bonus", "experienceRequirements": { "@type": "OccupationalExperienceRequirements", "monthsOfExperience": 36 }, "educationRequirements": "Doctorate", "url": "https://fewerjobs.com/jobs/summit-therapeutics/corporate-counsel-clinical-contracts-ecb97733" } }, { "@type": "ListItem", "position": 4, "url": "https://fewerjobs.com/jobs/summit-therapeutics/associate-director-clinical-supplies-global-planning-and-operations-83ea4688", "item": { "@context": "https://schema.org", "@type": "JobPosting", "title": "Associate Director, Clinical Supplies-Global Planning & Operations", "description": "

Associate Director, Clinical Supplies-Global Planning & Operations at Summit Therapeutics - Palo Alto, CA (US) - Associate Director, Clinical Supplies-Global Planning & Operations Palo Alto, CA (US) About Summit: Summit Therapeutics Inc. is a biopharmaceutical oncology company with a mission focused on improving quality of life, increasing potential duration of life, and resolving serious unmet medical needs. At Summit, we believe in building a team of world class professionals who are passionate about this mission, and it is our people who drive this mission to reality. Summit's core values include integrity, passion for excellence, purposeful urgency, collaboration, and our commitment to people. Our employees are truly the heart and soul of our culture, and they are invaluable in shaping our journey toward excellence. Summit's team is inspired to touch and help change lives through Summit's clinical studies in the field of oncology. Summit has multiple global Phase 3 clinical studies, including: Non-small Cell Lung Cancer (NSCLC) - HARMONi: Phase 3 clinical study which was intended to evaluate ivonescimab combined with chemotherapy compared to placebo plus chemotherapy in patients with EGFR-mutated, locally advanced or metastatic non-squamous NSCLC who were previously treated with a 3rd generation EGFR TKI. - HARMONi-3: Phase 3 clinical study which is intended to evaluate ivonescimab combined with chemotherapy compared to pembrolizumab combined with chemotherapy in patients with first-line metastatic NSCLC. - HARMONi-7: Phase 3 clinical study which is intended to evaluate ivonescimab monotherapy compared to pembrolizumab monotherapy in patients with first-line metastatic NSCLC. Colorectal Cancer (CRC) - HARMONi-GI3: Phase 3 clinical study intended to evaluate ivonescimab in combination with chemotherapy compared with bevacizumab

", "datePosted": "2026-05-26T12:42:57.000Z", "employmentType": "CONTRACTOR", "identifier": { "@type": "PropertyValue", "name": "Summit Therapeutics", "value": "83ea4688691ead8eb6386a94bffea9c2" }, "hiringOrganization": { "@type": "Organization", "name": "Summit Therapeutics" }, "jobLocation": { "@type": "Place", "address": { "@type": "PostalAddress", "addressCountry": "US", "addressLocality": "Palo Alto" } }, "estimatedSalary": { "@type": "MonetaryAmount", "currency": "USD", "value": { "@type": "QuantitativeValue", "minValue": 175000, "maxValue": 200000, "unitText": "YEAR" }, "description": "Total compensation" }, "directApply": false, "incentiveCompensation": "Bonus", "experienceRequirements": { "@type": "OccupationalExperienceRequirements", "monthsOfExperience": 96 }, "educationRequirements": "Masters", "url": "https://fewerjobs.com/jobs/summit-therapeutics/associate-director-clinical-supplies-global-planning-and-operations-83ea4688" } }, { "@type": "ListItem", "position": 5, "url": "https://fewerjobs.com/jobs/summit-therapeutics/lead-regional-medical-science-director-ec000df2", "item": { "@context": "https://schema.org", "@type": "JobPosting", "title": "Lead, Regional Medical Science Director", "description": "

Lead, Regional Medical Science Director at Summit Therapeutics - Raleigh, North Carolina, United States - Lead, Regional Medical Science Director Raleigh, North Carolina, United States About Summit: Summit Therapeutics Inc. is a biopharmaceutical oncology company with a mission focused on improving quality of life, increasing potential duration of life, and resolving serious unmet medical needs. At Summit, we believe in building a team of world class professionals who are passionate about this mission, and it is our people who drive this mission to reality. Summit's core values include integrity, passion for excellence, purposeful urgency, collaboration, and our commitment to people. Our employees are truly the heart and soul of our culture, and they are invaluable in shaping our journey toward excellence. Summit's team is inspired to touch and help change lives through Summit's clinical studies in the field of oncology. Summit has multiple global Phase 3 clinical studies, including: Non-small Cell Lung Cancer (NSCLC) - HARMONi: Phase 3 clinical study which was intended to evaluate ivonescimab combined with chemotherapy compared to placebo plus chemotherapy in patients with EGFR-mutated, locally advanced or metastatic non-squamous NSCLC who were previously treated with a 3rd generation EGFR TKI. - HARMONi-3: Phase 3 clinical study which is intended to evaluate ivonescimab combined with chemotherapy compared to pembrolizumab combined with chemotherapy in patients with first-line metastatic NSCLC. - HARMONi-7: Phase 3 clinical study which is intended to evaluate ivonescimab monotherapy compared to pembrolizumab monotherapy in patients with first-line metastatic NSCLC. Colorectal Cancer (CRC) - HARMONi-GI3: Phase 3 clinical study intended to evaluate ivonescimab in combination with chemotherapy compared with bevacizumab plus

", "datePosted": "2026-05-22T18:15:17.000Z", "employmentType": "OTHER", "identifier": { "@type": "PropertyValue", "name": "Summit Therapeutics", "value": "ec000df2378537ae734fdd15cfda8eb2" }, "hiringOrganization": { "@type": "Organization", "name": "Summit Therapeutics" }, "jobLocation": { "@type": "Place", "address": { "@type": "PostalAddress", "addressCountry": "US", "addressLocality": "Raleigh" } }, "estimatedSalary": { "@type": "MonetaryAmount", "currency": "USD", "value": { "@type": "QuantitativeValue", "minValue": 250000, "maxValue": 270000, "unitText": "YEAR" }, "description": "Total compensation" }, "directApply": false, "incentiveCompensation": "Bonus", "experienceRequirements": { "@type": "OccupationalExperienceRequirements", "monthsOfExperience": 96 }, "educationRequirements": "Doctorate", "url": "https://fewerjobs.com/jobs/summit-therapeutics/lead-regional-medical-science-director-ec000df2" } }, { "@type": "ListItem", "position": 6, "url": "https://fewerjobs.com/jobs/summit-therapeutics/senior-medical-science-liaison-tx-and-nm-f9d73f57", "item": { "@context": "https://schema.org", "@type": "JobPosting", "title": "Senior Medical Science Liaison (TX & NM)", "description": "

Senior Medical Science Liaison (TX & NM) at Summit Therapeutics - Dallas, Texas, United States - Senior Medical Science Liaison (TX & NM) Dallas, Texas, United States About Summit: Summit Therapeutics Inc. is a biopharmaceutical oncology company with a mission focused on improving quality of life, increasing potential duration of life, and resolving serious unmet medical needs. At Summit, we believe in building a team of world class professionals who are passionate about this mission, and it is our people who drive this mission to reality. Summit's core values include integrity, passion for excellence, purposeful urgency, collaboration, and our commitment to people. Our employees are truly the heart and soul of our culture, and they are invaluable in shaping our journey toward excellence. Summit's team is inspired to touch and help change lives through Summit's clinical studies in the field of oncology. Summit has multiple global Phase 3 clinical studies, including: Non-small Cell Lung Cancer (NSCLC) - HARMONi: Phase 3 clinical study which was intended to evaluate ivonescimab combined with chemotherapy compared to placebo plus chemotherapy in patients with EGFR-mutated, locally advanced or metastatic non-squamous NSCLC who were previously treated with a 3rd generation EGFR TKI. - HARMONi-3: Phase 3 clinical study which is intended to evaluate ivonescimab combined with chemotherapy compared to pembrolizumab combined with chemotherapy in patients with first-line metastatic NSCLC. - HARMONi-7: Phase 3 clinical study which is intended to evaluate ivonescimab monotherapy compared to pembrolizumab monotherapy in patients with first-line metastatic NSCLC. Colorectal Cancer (CRC) - HARMONi-GI3: Phase 3 clinical study intended to evaluate ivonescimab in combination with chemotherapy compared with bevacizumab

", "datePosted": "2026-05-22T18:05:18.000Z", "employmentType": "OTHER", "identifier": { "@type": "PropertyValue", "name": "Summit Therapeutics", "value": "f9d73f579afc3220c8850eee31a09019" }, "hiringOrganization": { "@type": "Organization", "name": "Summit Therapeutics" }, "jobLocation": { "@type": "Place", "address": { "@type": "PostalAddress", "addressCountry": "US", "addressLocality": "Dallas" } }, "estimatedSalary": { "@type": "MonetaryAmount", "currency": "USD", "value": { "@type": "QuantitativeValue", "minValue": 200000, "maxValue": 235000, "unitText": "YEAR" }, "description": "Total compensation" }, "directApply": false, "incentiveCompensation": "Bonus", "experienceRequirements": { "@type": "OccupationalExperienceRequirements", "monthsOfExperience": 60 }, "educationRequirements": "Doctorate", "url": "https://fewerjobs.com/jobs/summit-therapeutics/senior-medical-science-liaison-tx-and-nm-f9d73f57" } }, { "@type": "ListItem", "position": 7, "url": "https://fewerjobs.com/jobs/summit-therapeutics/senior-medical-science-liaison-ny-and-nj-8621cb57", "item": { "@context": "https://schema.org", "@type": "JobPosting", "title": "Senior Medical Science Liaison(NY & NJ)", "description": "

Senior Medical Science Liaison(NY & NJ) at Summit Therapeutics - Brooklyn, New York, United States - Senior Medical Science Liaison(NY & NJ) Brooklyn, New York, United States About Summit: Summit Therapeutics Inc. is a biopharmaceutical oncology company with a mission focused on improving quality of life, increasing potential duration of life, and resolving serious unmet medical needs. At Summit, we believe in building a team of world class professionals who are passionate about this mission, and it is our people who drive this mission to reality. Summit's core values include integrity, passion for excellence, purposeful urgency, collaboration, and our commitment to people. Our employees are truly the heart and soul of our culture, and they are invaluable in shaping our journey toward excellence. Summit's team is inspired to touch and help change lives through Summit's clinical studies in the field of oncology. Summit has multiple global Phase 3 clinical studies, including: Non-small Cell Lung Cancer (NSCLC) - HARMONi: Phase 3 clinical study which was intended to evaluate ivonescimab combined with chemotherapy compared to placebo plus chemotherapy in patients with EGFR-mutated, locally advanced or metastatic non-squamous NSCLC who were previously treated with a 3rd generation EGFR TKI. - HARMONi-3: Phase 3 clinical study which is intended to evaluate ivonescimab combined with chemotherapy compared to pembrolizumab combined with chemotherapy in patients with first-line metastatic NSCLC. - HARMONi-7: Phase 3 clinical study which is intended to evaluate ivonescimab monotherapy compared to pembrolizumab monotherapy in patients with first-line metastatic NSCLC. Colorectal Cancer (CRC) - HARMONi-GI3: Phase 3 clinical study intended to evaluate ivonescimab in combination with chemotherapy compared with bevacizumab

", "datePosted": "2026-05-22T18:04:48.000Z", "employmentType": "OTHER", "identifier": { "@type": "PropertyValue", "name": "Summit Therapeutics", "value": "8621cb5762d9e301f4e5780f97f70677" }, "hiringOrganization": { "@type": "Organization", "name": "Summit Therapeutics" }, "jobLocation": { "@type": "Place", "address": { "@type": "PostalAddress", "addressCountry": "US", "addressLocality": "Brooklyn" } }, "estimatedSalary": { "@type": "MonetaryAmount", "currency": "USD", "value": { "@type": "QuantitativeValue", "minValue": 200000, "maxValue": 235000, "unitText": "YEAR" }, "description": "Total compensation" }, "directApply": false, "incentiveCompensation": "Bonus", "experienceRequirements": { "@type": "OccupationalExperienceRequirements", "monthsOfExperience": 60 }, "educationRequirements": "Doctorate", "url": "https://fewerjobs.com/jobs/summit-therapeutics/senior-medical-science-liaison-ny-and-nj-8621cb57" } }, { "@type": "ListItem", "position": 8, "url": "https://fewerjobs.com/jobs/summit-therapeutics/senior-medical-science-liaison-ks-mo-ok-ar-7ff826bc", "item": { "@context": "https://schema.org", "@type": "JobPosting", "title": "Senior Medical Science Liaison (KS, MO, OK, AR)", "description": "

Senior Medical Science Liaison (KS, MO, OK, AR) at Summit Therapeutics - Kansas City, Missouri, United States - Senior Medical Science Liaison (KS, MO, OK, AR) Kansas City, Missouri, United States About Summit: Summit Therapeutics Inc. is a biopharmaceutical oncology company with a mission focused on improving quality of life, increasing potential duration of life, and resolving serious unmet medical needs. At Summit, we believe in building a team of world class professionals who are passionate about this mission, and it is our people who drive this mission to reality. Summit's core values include integrity, passion for excellence, purposeful urgency, collaboration, and our commitment to people. Our employees are truly the heart and soul of our culture, and they are invaluable in shaping our journey toward excellence. Summit's team is inspired to touch and help change lives through Summit's clinical studies in the field of oncology. Summit has multiple global Phase 3 clinical studies, including: Non-small Cell Lung Cancer (NSCLC) - HARMONi: Phase 3 clinical study which was intended to evaluate ivonescimab combined with chemotherapy compared to placebo plus chemotherapy in patients with EGFR-mutated, locally advanced or metastatic non-squamous NSCLC who were previously treated with a 3rd generation EGFR TKI. - HARMONi-3: Phase 3 clinical study which is intended to evaluate ivonescimab combined with chemotherapy compared to pembrolizumab combined with chemotherapy in patients with first-line metastatic NSCLC. - HARMONi-7: Phase 3 clinical study which is intended to evaluate ivonescimab monotherapy compared to pembrolizumab monotherapy in patients with first-line metastatic NSCLC. Colorectal Cancer (CRC) - HARMONi-GI3: Phase 3 clinical study intended to evaluate ivonescimab in combination with chemotherapy compared

", "datePosted": "2026-05-22T18:03:37.000Z", "employmentType": "OTHER", "identifier": { "@type": "PropertyValue", "name": "Summit Therapeutics", "value": "7ff826bcb9c7a875630bc0f42b2c5c9b" }, "hiringOrganization": { "@type": "Organization", "name": "Summit Therapeutics" }, "jobLocation": { "@type": "Place", "address": { "@type": "PostalAddress", "addressCountry": "US", "addressLocality": "Kansas City" } }, "estimatedSalary": { "@type": "MonetaryAmount", "currency": "USD", "value": { "@type": "QuantitativeValue", "minValue": 200000, "maxValue": 235000, "unitText": "YEAR" }, "description": "Total compensation" }, "directApply": false, "incentiveCompensation": "Bonus", "experienceRequirements": { "@type": "OccupationalExperienceRequirements", "monthsOfExperience": 60 }, "educationRequirements": "Doctorate", "url": "https://fewerjobs.com/jobs/summit-therapeutics/senior-medical-science-liaison-ks-mo-ok-ar-7ff826bc" } }, { "@type": "ListItem", "position": 9, "url": "https://fewerjobs.com/jobs/summit-therapeutics/senior-director-of-technical-qa-gmp-33c4239a", "item": { "@context": "https://schema.org", "@type": "JobPosting", "title": "Senior Director of Technical QA (GMP)", "description": "

Senior Director of Technical QA (GMP) at Summit Therapeutics - Palo Alto, CA (US) - Senior Director of Technical QA (GMP) Palo Alto, CA (US) About Summit: Summit Therapeutics Inc. is a biopharmaceutical oncology company with a mission focused on improving quality of life, increasing potential duration of life, and resolving serious unmet medical needs. At Summit, we believe in building a team of world class professionals who are passionate about this mission, and it is our people who drive this mission to reality. Summit's core values include integrity, passion for excellence, purposeful urgency, collaboration, and our commitment to people. Our employees are truly the heart and soul of our culture, and they are invaluable in shaping our journey toward excellence. Summit's team is inspired to touch and help change lives through Summit's clinical studies in the field of oncology. Summit has multiple global Phase 3 clinical studies, including: Non-small Cell Lung Cancer (NSCLC) - HARMONi: Phase 3 clinical study which was intended to evaluate ivonescimab combined with chemotherapy compared to placebo plus chemotherapy in patients with EGFR-mutated, locally advanced or metastatic non-squamous NSCLC who were previously treated with a 3rd generation EGFR TKI. - HARMONi-3: Phase 3 clinical study which is intended to evaluate ivonescimab combined with chemotherapy compared to pembrolizumab combined with chemotherapy in patients with first-line metastatic NSCLC. - HARMONi-7: Phase 3 clinical study which is intended to evaluate ivonescimab monotherapy compared to pembrolizumab monotherapy in patients with first-line metastatic NSCLC. Colorectal Cancer (CRC) - HARMONi-GI3: Phase 3 clinical study intended to evaluate ivonescimab in combination with chemotherapy compared with bevacizumab plus

", "datePosted": "2026-05-20T18:06:07.000Z", "employmentType": "CONTRACTOR", "identifier": { "@type": "PropertyValue", "name": "Summit Therapeutics", "value": "33c4239a3457666234ce1a11f2cd6ce7" }, "hiringOrganization": { "@type": "Organization", "name": "Summit Therapeutics" }, "jobLocation": { "@type": "Place", "address": { "@type": "PostalAddress", "addressCountry": "US", "addressLocality": "Palo Alto" } }, "estimatedSalary": { "@type": "MonetaryAmount", "currency": "USD", "value": { "@type": "QuantitativeValue", "minValue": 217000, "maxValue": 271000, "unitText": "YEAR" }, "description": "Total compensation" }, "directApply": false, "incentiveCompensation": "Bonus", "experienceRequirements": { "@type": "OccupationalExperienceRequirements", "monthsOfExperience": 96 }, "educationRequirements": "Doctorate", "url": "https://fewerjobs.com/jobs/summit-therapeutics/senior-director-of-technical-qa-gmp-33c4239a" } }, { "@type": "ListItem", "position": 10, "url": "https://fewerjobs.com/jobs/summit-therapeutics/vice-president-us-marketing-6f1c2998", "item": { "@context": "https://schema.org", "@type": "JobPosting", "title": "Vice President, US Marketing", "description": "

Vice President, US Marketing at Summit Therapeutics - Princeton, NJ (US) - Vice President, US Marketing Princeton, NJ (US) About Summit: Summit Therapeutics Inc. is a biopharmaceutical oncology company with a mission focused on improving quality of life, increasing potential duration of life, and resolving serious unmet medical needs. At Summit, we believe in building a team of world class professionals who are passionate about this mission, and it is our people who drive this mission to reality. Summit's core values include integrity, passion for excellence, purposeful urgency, collaboration, and our commitment to people. Our employees are truly the heart and soul of our culture, and they are invaluable in shaping our journey toward excellence. Summit's team is inspired to touch and help change lives through Summit's clinical studies in the field of oncology. Summit has multiple global Phase 3 clinical studies, including: Non-small Cell Lung Cancer (NSCLC) - HARMONi: Phase 3 clinical study which was intended to evaluate ivonescimab combined with chemotherapy compared to placebo plus chemotherapy in patients with EGFR-mutated, locally advanced or metastatic non-squamous NSCLC who were previously treated with a 3rd generation EGFR TKI. - HARMONi-3: Phase 3 clinical study which is intended to evaluate ivonescimab combined with chemotherapy compared to pembrolizumab combined with chemotherapy in patients with first-line metastatic NSCLC. - HARMONi-7: Phase 3 clinical study which is intended to evaluate ivonescimab monotherapy compared to pembrolizumab monotherapy in patients with first-line metastatic NSCLC. Colorectal Cancer (CRC) - HARMONi-GI3: Phase 3 clinical study intended to evaluate ivonescimab in combination with chemotherapy compared with bevacizumab plus chemotherapy. Ivonescimab is

", "datePosted": "2026-05-19T15:33:43.000Z", "employmentType": "OTHER", "identifier": { "@type": "PropertyValue", "name": "Summit Therapeutics", "value": "6f1c29981ea3e0d27f151f551ab6d1c4" }, "hiringOrganization": { "@type": "Organization", "name": "Summit Therapeutics" }, "jobLocation": { "@type": "Place", "address": { "@type": "PostalAddress", "addressCountry": "US", "addressLocality": "Princeton" } }, "estimatedSalary": { "@type": "MonetaryAmount", "currency": "USD", "value": { "@type": "QuantitativeValue", "minValue": 315000, "maxValue": 350000, "unitText": "YEAR" }, "description": "Total compensation" }, "directApply": false, "incentiveCompensation": "Bonus", "experienceRequirements": { "@type": "OccupationalExperienceRequirements", "monthsOfExperience": 96 }, "educationRequirements": "Doctorate", "url": "https://fewerjobs.com/jobs/summit-therapeutics/vice-president-us-marketing-6f1c2998" } }, { "@type": "ListItem", "position": 11, "url": "https://fewerjobs.com/jobs/summit-therapeutics/associate-director-regulatory-cmc-9ba5e995", "item": { "@context": "https://schema.org", "@type": "JobPosting", "title": "Associate Director, Regulatory CMC", "description": "

Associate Director, Regulatory CMC at Summit Therapeutics - Palo Alto, CA (US) - Associate Director, Regulatory CMC Palo Alto, CA (US) About Summit: Summit Therapeutics Inc. is a biopharmaceutical oncology company with a mission focused on improving quality of life, increasing potential duration of life, and resolving serious unmet medical needs. At Summit, we believe in building a team of world class professionals who are passionate about this mission, and it is our people who drive this mission to reality. Summit's core values include integrity, passion for excellence, purposeful urgency, collaboration, and our commitment to people. Our employees are truly the heart and soul of our culture, and they are invaluable in shaping our journey toward excellence. Summit's team is inspired to touch and help change lives through Summit's clinical studies in the field of oncology. Summit has multiple global Phase 3 clinical studies, including: Non-small Cell Lung Cancer (NSCLC) - HARMONi: Phase 3 clinical study which was intended to evaluate ivonescimab combined with chemotherapy compared to placebo plus chemotherapy in patients with EGFR-mutated, locally advanced or metastatic non-squamous NSCLC who were previously treated with a 3rd generation EGFR TKI. - HARMONi-3: Phase 3 clinical study which is intended to evaluate ivonescimab combined with chemotherapy compared to pembrolizumab combined with chemotherapy in patients with first-line metastatic NSCLC. - HARMONi-7: Phase 3 clinical study which is intended to evaluate ivonescimab monotherapy compared to pembrolizumab monotherapy in patients with first-line metastatic NSCLC. Colorectal Cancer (CRC) - HARMONi-GI3: Phase 3 clinical study intended to evaluate ivonescimab in combination with chemotherapy compared with bevacizumab plus chemotherapy. Ivonescimab

", "datePosted": "2026-05-05T17:04:36.000Z", "employmentType": "OTHER", "identifier": { "@type": "PropertyValue", "name": "Summit Therapeutics", "value": "9ba5e99509fc9b81134b2dd7c0863e76" }, "hiringOrganization": { "@type": "Organization", "name": "Summit Therapeutics" }, "jobLocation": { "@type": "Place", "address": { "@type": "PostalAddress", "addressCountry": "US", "addressLocality": "Palo Alto" } }, "estimatedSalary": { "@type": "MonetaryAmount", "currency": "USD", "value": { "@type": "QuantitativeValue", "minValue": 194000, "maxValue": 199000, "unitText": "YEAR" }, "description": "Total compensation" }, "directApply": false, "incentiveCompensation": "Bonus", "experienceRequirements": { "@type": "OccupationalExperienceRequirements", "monthsOfExperience": 96 }, "educationRequirements": "Masters", "url": "https://fewerjobs.com/jobs/summit-therapeutics/associate-director-regulatory-cmc-9ba5e995" } }, { "@type": "ListItem", "position": 12, "url": "https://fewerjobs.com/jobs/summit-therapeutics/senior-principal-engineer-associate-director-drug-product-msat-92b30f39", "item": { "@context": "https://schema.org", "@type": "JobPosting", "title": "Senior Principal Engineer/Associate Director, Drug Product MSAT", "description": "

Senior Principal Engineer/Associate Director, Drug Product MSAT at Summit Therapeutics - Princeton, NJ - Senior Principal Engineer/Associate Director, Drug Product MSAT Princeton, NJ About Summit: Summit Therapeutics Inc. is a biopharmaceutical oncology company with a mission focused on improving quality of life, increasing potential duration of life, and resolving serious unmet medical needs. At Summit, we believe in building a team of world class professionals who are passionate about this mission, and it is our people who drive this mission to reality. Summit's core values include integrity, passion for excellence, purposeful urgency, collaboration, and our commitment to people. Our employees are truly the heart and soul of our culture, and they are invaluable in shaping our journey toward excellence. Summit's team is inspired to touch and help change lives through Summit's clinical studies in the field of oncology. Summit has multiple global Phase 3 clinical studies, including: Non-small Cell Lung Cancer (NSCLC) - HARMONi: Phase 3 clinical study which was intended to evaluate ivonescimab combined with chemotherapy compared to placebo plus chemotherapy in patients with EGFR-mutated, locally advanced or metastatic non-squamous NSCLC who were previously treated with a 3rd generation EGFR TKI. - HARMONi-3: Phase 3 clinical study which is intended to evaluate ivonescimab combined with chemotherapy compared to pembrolizumab combined with chemotherapy in patients with first-line metastatic NSCLC. - HARMONi-7: Phase 3 clinical study which is intended to evaluate ivonescimab monotherapy compared to pembrolizumab monotherapy in patients with first-line metastatic NSCLC. Colorectal Cancer (CRC) - HARMONi-GI3: Phase 3 clinical study intended to evaluate ivonescimab in combination with chemotherapy compared with bevacizumab plus chemotherapy.

", "datePosted": "2026-04-27T22:34:29.000Z", "employmentType": "OTHER", "identifier": { "@type": "PropertyValue", "name": "Summit Therapeutics", "value": "92b30f39d60a1211e9c1a3ef9b5f4f1b" }, "hiringOrganization": { "@type": "Organization", "name": "Summit Therapeutics" }, "jobLocation": { "@type": "Place", "address": { "@type": "PostalAddress", "addressCountry": "US", "addressLocality": "Princeton" } }, "estimatedSalary": { "@type": "MonetaryAmount", "currency": "USD", "value": { "@type": "QuantitativeValue", "minValue": 180000, "maxValue": 195000, "unitText": "YEAR" }, "description": "Total compensation" }, "directApply": false, "incentiveCompensation": "Bonus", "experienceRequirements": { "@type": "OccupationalExperienceRequirements", "monthsOfExperience": 120 }, "educationRequirements": "Doctorate", "url": "https://fewerjobs.com/jobs/summit-therapeutics/senior-principal-engineer-associate-director-drug-product-msat-92b30f39" } }, { "@type": "ListItem", "position": 13, "url": "https://fewerjobs.com/jobs/summit-therapeutics/senior-manager-clinical-site-partner-germany-02497b5e", "item": { "@context": "https://schema.org", "@type": "JobPosting", "title": "Senior Manager, Clinical Site Partner (Germany)", "description": "

Senior Manager, Clinical Site Partner (Germany) at Summit Therapeutics - Remote-Field (Germany) - Senior Manager, Clinical Site Partner (Germany) Remote-Field (Germany) About Summit: Summit Therapeutics Inc. is a biopharmaceutical oncology company with a mission focused on improving quality of life, increasing potential duration of life, and resolving serious unmet medical needs. At Summit, we believe in building a team of world class professionals who are passionate about this mission, and it is our people who drive this mission to reality. Summit's core values include integrity, passion for excellence, purposeful urgency, collaboration, and our commitment to people. Our employees are truly the heart and soul of our culture, and they are invaluable in shaping our journey toward excellence. Summit's team is inspired to touch and help change lives through Summit's clinical studies in the field of oncology. Summit has multiple global Phase 3 clinical studies, including: Non-small Cell Lung Cancer (NSCLC) - HARMONi: Phase 3 clinical study which was intended to evaluate ivonescimab combined with chemotherapy compared to placebo plus chemotherapy in patients with EGFR-mutated, locally advanced or metastatic non-squamous NSCLC who were previously treated with a 3rd generation EGFR TKI. - HARMONi-3: Phase 3 clinical study which is intended to evaluate ivonescimab combined with chemotherapy compared to pembrolizumab combined with chemotherapy in patients with first-line metastatic NSCLC. - HARMONi-7: Phase 3 clinical study which is intended to evaluate ivonescimab monotherapy compared to pembrolizumab monotherapy in patients with first-line metastatic NSCLC. Colorectal Cancer (CRC) - HARMONi-GI3: Phase 3 clinical study intended to evaluate ivonescimab in combination with chemotherapy compared with bevacizumab plus chemotherapy. Ivonescimab

", "datePosted": "2026-04-24T16:29:09.000Z", "employmentType": "CONTRACTOR", "identifier": { "@type": "PropertyValue", "name": "Summit Therapeutics", "value": "02497b5e5a2bb55acc3d8fb1714a3a4a" }, "hiringOrganization": { "@type": "Organization", "name": "Summit Therapeutics" }, "jobLocationType": "TELECOMMUTE", "applicantLocationRequirements": { "@type": "Country", "name": "DE" }, "directApply": false, "incentiveCompensation": "Bonus", "experienceRequirements": { "@type": "OccupationalExperienceRequirements", "monthsOfExperience": 60 }, "educationRequirements": "Doctorate", "url": "https://fewerjobs.com/jobs/summit-therapeutics/senior-manager-clinical-site-partner-germany-02497b5e" } }, { "@type": "ListItem", "position": 14, "url": "https://fewerjobs.com/jobs/summit-therapeutics/executive-director-us-market-access-strategy-c852f69b", "item": { "@context": "https://schema.org", "@type": "JobPosting", "title": "Executive Director, US Market Access Strategy", "description": "

Executive Director, US Market Access Strategy at Summit Therapeutics - Princeton, NJ - Executive Director, US Market Access Strategy Princeton, NJ About Summit: Summit Therapeutics Inc. is a biopharmaceutical oncology company with a mission focused on improving quality of life, increasing potential duration of life, and resolving serious unmet medical needs. At Summit, we believe in building a team of world class professionals who are passionate about this mission, and it is our people who drive this mission to reality. Summit's core values include integrity, passion for excellence, purposeful urgency, collaboration, and our commitment to people. Our employees are truly the heart and soul of our culture, and they are invaluable in shaping our journey toward excellence. Summit's team is inspired to touch and help change lives through Summit's clinical studies in the field of oncology. Summit has multiple global Phase 3 clinical studies, including: Non-small Cell Lung Cancer (NSCLC) - HARMONi: Phase 3 clinical study which was intended to evaluate ivonescimab combined with chemotherapy compared to placebo plus chemotherapy in patients with EGFR-mutated, locally advanced or metastatic non-squamous NSCLC who were previously treated with a 3rd generation EGFR TKI. - HARMONi-3: Phase 3 clinical study which is intended to evaluate ivonescimab combined with chemotherapy compared to pembrolizumab combined with chemotherapy in patients with first-line metastatic NSCLC. - HARMONi-7: Phase 3 clinical study which is intended to evaluate ivonescimab monotherapy compared to pembrolizumab monotherapy in patients with first-line metastatic NSCLC. Colorectal Cancer (CRC) - HARMONi-GI3: Phase 3 clinical study intended to evaluate ivonescimab in combination with chemotherapy compared with bevacizumab plus chemotherapy. Ivonescimab

", "datePosted": "2026-04-17T21:04:08.000Z", "employmentType": "OTHER", "identifier": { "@type": "PropertyValue", "name": "Summit Therapeutics", "value": "c852f69b15998cda8de0a20cd61a3d2d" }, "hiringOrganization": { "@type": "Organization", "name": "Summit Therapeutics" }, "jobLocation": { "@type": "Place", "address": { "@type": "PostalAddress", "addressCountry": "US", "addressLocality": "Princeton" } }, "estimatedSalary": { "@type": "MonetaryAmount", "currency": "USD", "value": { "@type": "QuantitativeValue", "minValue": 245000, "maxValue": 307000, "unitText": "YEAR" }, "description": "Total compensation" }, "directApply": false, "incentiveCompensation": "Bonus", "experienceRequirements": { "@type": "OccupationalExperienceRequirements", "monthsOfExperience": 96 }, "educationRequirements": "Bachelors", "url": "https://fewerjobs.com/jobs/summit-therapeutics/executive-director-us-market-access-strategy-c852f69b" } }, { "@type": "ListItem", "position": 15, "url": "https://fewerjobs.com/jobs/summit-therapeutics/clinical-trial-manager-a5a52394", "item": { "@context": "https://schema.org", "@type": "JobPosting", "title": "Clinical Trial Manager", "description": "

Clinical Trial Manager at Summit Therapeutics - Palo Alto, CA (US) - Clinical Trial Manager Palo Alto, CA (US) About Summit: Summit Therapeutics Inc. is a biopharmaceutical oncology company with a mission focused on improving quality of life, increasing potential duration of life, and resolving serious unmet medical needs. At Summit, we believe in building a team of world class professionals who are passionate about this mission, and it is our people who drive this mission to reality. Summit's core values include integrity, passion for excellence, purposeful urgency, collaboration, and our commitment to people. Our employees are truly the heart and soul of our culture, and they are invaluable in shaping our journey toward excellence. Summit's team is inspired to touch and help change lives through Summit's clinical studies in the field of oncology. Summit has multiple global Phase 3 clinical studies, including: Non-small Cell Lung Cancer (NSCLC) - HARMONi: Phase 3 clinical study which was intended to evaluate ivonescimab combined with chemotherapy compared to placebo plus chemotherapy in patients with EGFR-mutated, locally advanced or metastatic non-squamous NSCLC who were previously treated with a 3rd generation EGFR TKI. - HARMONi-3: Phase 3 clinical study which is intended to evaluate ivonescimab combined with chemotherapy compared to pembrolizumab combined with chemotherapy in patients with first-line metastatic NSCLC. - HARMONi-7: Phase 3 clinical study which is intended to evaluate ivonescimab monotherapy compared to pembrolizumab monotherapy in patients with first-line metastatic NSCLC. Colorectal Cancer (CRC) - HARMONi-GI3: Phase 3 clinical study intended to evaluate ivonescimab in combination with chemotherapy compared with bevacizumab plus chemotherapy. Ivonescimab is

", "datePosted": "2026-04-16T14:57:06.000Z", "employmentType": "OTHER", "identifier": { "@type": "PropertyValue", "name": "Summit Therapeutics", "value": "a5a523946a4e2415e144cde98e54ddcb" }, "hiringOrganization": { "@type": "Organization", "name": "Summit Therapeutics" }, "jobLocation": { "@type": "Place", "address": { "@type": "PostalAddress", "addressCountry": "US", "addressLocality": "Palo Alto" } }, "estimatedSalary": { "@type": "MonetaryAmount", "currency": "USD", "value": { "@type": "QuantitativeValue", "minValue": 140000, "maxValue": 150000, "unitText": "YEAR" }, "description": "Total compensation" }, "directApply": false, "incentiveCompensation": "Bonus", "experienceRequirements": { "@type": "OccupationalExperienceRequirements", "monthsOfExperience": 60 }, "educationRequirements": "Bachelors", "url": "https://fewerjobs.com/jobs/summit-therapeutics/clinical-trial-manager-a5a52394" } }, { "@type": "ListItem", "position": 16, "url": "https://fewerjobs.com/jobs/summit-therapeutics/clinical-supplies-manager-7cbdee54", "item": { "@context": "https://schema.org", "@type": "JobPosting", "title": "Clinical Supplies Manager", "description": "

Clinical Supplies Manager at Summit Therapeutics - Remote - Clinical Supplies Manager Remote About Summit: Summit Therapeutics Inc. is a biopharmaceutical oncology company with a mission focused on improving quality of life, increasing potential duration of life, and resolving serious unmet medical needs. At Summit, we believe in building a team of world class professionals who are passionate about this mission, and it is our people who drive this mission to reality. Summit's core values include integrity, passion for excellence, purposeful urgency, collaboration, and our commitment to people. Our employees are truly the heart and soul of our culture, and they are invaluable in shaping our journey toward excellence. Summit's team is inspired to touch and help change lives through Summit's clinical studies in the field of oncology. Summit has multiple global Phase 3 clinical studies, including: Non-small Cell Lung Cancer (NSCLC) - HARMONi: Phase 3 clinical study which was intended to evaluate ivonescimab combined with chemotherapy compared to placebo plus chemotherapy in patients with EGFR-mutated, locally advanced or metastatic non-squamous NSCLC who were previously treated with a 3rd generation EGFR TKI. - HARMONi-3: Phase 3 clinical study which is intended to evaluate ivonescimab combined with chemotherapy compared to pembrolizumab combined with chemotherapy in patients with first-line metastatic NSCLC. - HARMONi-7: Phase 3 clinical study which is intended to evaluate ivonescimab monotherapy compared to pembrolizumab monotherapy in patients with first-line metastatic NSCLC. Colorectal Cancer (CRC) - HARMONi-GI3: Phase 3 clinical study intended to evaluate ivonescimab in combination with chemotherapy compared with bevacizumab plus chemotherapy. Ivonescimab is an investigational therapy

", "datePosted": "2026-04-01T16:11:31.000Z", "employmentType": "CONTRACTOR", "identifier": { "@type": "PropertyValue", "name": "Summit Therapeutics", "value": "7cbdee5465fce8046ccba9bfe43af374" }, "hiringOrganization": { "@type": "Organization", "name": "Summit Therapeutics" }, "jobLocationType": "TELECOMMUTE", "applicantLocationRequirements": { "@type": "Country", "name": "UNKNOWN" }, "estimatedSalary": { "@type": "MonetaryAmount", "currency": "USD", "value": { "@type": "QuantitativeValue", "minValue": 120000, "maxValue": 145000, "unitText": "YEAR" }, "description": "Total compensation" }, "directApply": false, "incentiveCompensation": "Bonus", "experienceRequirements": { "@type": "OccupationalExperienceRequirements", "monthsOfExperience": 60 }, "educationRequirements": "Bachelors", "url": "https://fewerjobs.com/jobs/summit-therapeutics/clinical-supplies-manager-7cbdee54" } }, { "@type": "ListItem", "position": 17, "url": "https://fewerjobs.com/jobs/summit-therapeutics/director-biostatistics-bfa2708e", "item": { "@context": "https://schema.org", "@type": "JobPosting", "title": "Director, Biostatistics", "description": "

Director, Biostatistics at Summit Therapeutics - Palo Alto, California, United States - Director, Biostatistics Palo Alto, California, United States About Summit: Summit Therapeutics Inc. is a biopharmaceutical oncology company with a mission focused on improving quality of life, increasing potential duration of life, and resolving serious unmet medical needs. At Summit, we believe in building a team of world class professionals who are passionate about this mission, and it is our people who drive this mission to reality. Summit's core values include integrity, passion for excellence, purposeful urgency, collaboration, and our commitment to people. Our employees are truly the heart and soul of our culture, and they are invaluable in shaping our journey toward excellence. Summit's team is inspired to touch and help change lives through Summit's clinical studies in the field of oncology. Summit has multiple global Phase 3 clinical studies, including: Non-small Cell Lung Cancer (NSCLC) - HARMONi: Phase 3 clinical study which was intended to evaluate ivonescimab combined with chemotherapy compared to placebo plus chemotherapy in patients with EGFR-mutated, locally advanced or metastatic non-squamous NSCLC who were previously treated with a 3rd generation EGFR TKI. - HARMONi-3: Phase 3 clinical study which is intended to evaluate ivonescimab combined with chemotherapy compared to pembrolizumab combined with chemotherapy in patients with first-line metastatic NSCLC. - HARMONi-7: Phase 3 clinical study which is intended to evaluate ivonescimab monotherapy compared to pembrolizumab monotherapy in patients with first-line metastatic NSCLC. Colorectal Cancer (CRC) - HARMONi-GI3: Phase 3 clinical study intended to evaluate ivonescimab in combination with chemotherapy compared with bevacizumab plus chemotherapy. Ivonescimab is

", "datePosted": "2026-03-18T13:22:19.000Z", "employmentType": "OTHER", "identifier": { "@type": "PropertyValue", "name": "Summit Therapeutics", "value": "bfa2708e8b6b8e3e2025cee93aa43216" }, "hiringOrganization": { "@type": "Organization", "name": "Summit Therapeutics" }, "jobLocation": { "@type": "Place", "address": { "@type": "PostalAddress", "addressCountry": "US", "addressLocality": "Palo Alto" } }, "estimatedSalary": { "@type": "MonetaryAmount", "currency": "USD", "value": { "@type": "QuantitativeValue", "minValue": 203000, "maxValue": 253000, "unitText": "YEAR" }, "description": "Total compensation" }, "directApply": false, "incentiveCompensation": "Bonus", "experienceRequirements": { "@type": "OccupationalExperienceRequirements", "monthsOfExperience": 96 }, "educationRequirements": "Doctorate", "url": "https://fewerjobs.com/jobs/summit-therapeutics/director-biostatistics-bfa2708e" } }, { "@type": "ListItem", "position": 18, "url": "https://fewerjobs.com/jobs/summit-therapeutics/sr-commercial-attorney-transactions-c04896de", "item": { "@context": "https://schema.org", "@type": "JobPosting", "title": "Sr. Commercial Attorney, Transactions", "description": "

Sr. Commercial Attorney, Transactions at Summit Therapeutics - Remote (US) - Sr. Commercial Attorney, Transactions Remote (US) About Summit: Summit Therapeutics Inc. is a biopharmaceutical oncology company with a mission focused on improving quality of life, increasing potential duration of life, and resolving serious unmet medical needs. At Summit, we believe in building a team of world class professionals who are passionate about this mission, and it is our people who drive this mission to reality. Summit's core values include integrity, passion for excellence, purposeful urgency, collaboration, and our commitment to people. Our employees are truly the heart and soul of our culture, and they are invaluable in shaping our journey toward excellence. Summit's team is inspired to touch and help change lives through Summit's clinical studies in the field of oncology. Summit has multiple global Phase 3 clinical studies, including: Non-small Cell Lung Cancer (NSCLC) - HARMONi: Phase 3 clinical study which was intended to evaluate ivonescimab combined with chemotherapy compared to placebo plus chemotherapy in patients with EGFR-mutated, locally advanced or metastatic non-squamous NSCLC who were previously treated with a 3rd generation EGFR TKI. - HARMONi-3: Phase 3 clinical study which is intended to evaluate ivonescimab combined with chemotherapy compared to pembrolizumab combined with chemotherapy in patients with first-line metastatic NSCLC. - HARMONi-7: Phase 3 clinical study which is intended to evaluate ivonescimab monotherapy compared to pembrolizumab monotherapy in patients with first-line metastatic NSCLC. Colorectal Cancer (CRC) - HARMONi-GI3: Phase 3 clinical study intended to evaluate ivonescimab in combination with chemotherapy compared with bevacizumab plus chemotherapy. Ivonescimab is an

", "datePosted": "2026-03-09T16:03:38.000Z", "employmentType": "CONTRACTOR", "identifier": { "@type": "PropertyValue", "name": "Summit Therapeutics", "value": "c04896ded1230a6e85e309b45b7dd1d1" }, "hiringOrganization": { "@type": "Organization", "name": "Summit Therapeutics" }, "jobLocationType": "TELECOMMUTE", "applicantLocationRequirements": { "@type": "Country", "name": "USA" }, "estimatedSalary": { "@type": "MonetaryAmount", "currency": "USD", "value": { "@type": "QuantitativeValue", "minValue": 217000, "maxValue": 271000, "unitText": "YEAR" }, "description": "Total compensation" }, "directApply": false, "incentiveCompensation": "Bonus", "experienceRequirements": { "@type": "OccupationalExperienceRequirements", "monthsOfExperience": 60 }, "educationRequirements": "Doctorate", "url": "https://fewerjobs.com/jobs/summit-therapeutics/sr-commercial-attorney-transactions-c04896de" } }, { "@type": "ListItem", "position": 19, "url": "https://fewerjobs.com/jobs/summit-therapeutics/senior-medical-science-liaison-nd-sd-mn-ia-mo-ne-2869277b", "item": { "@context": "https://schema.org", "@type": "JobPosting", "title": "Senior Medical Science Liaison (ND, SD, MN, IA, MO, NE)", "description": "

Senior Medical Science Liaison (ND, SD, MN, IA, MO, NE) at Summit Therapeutics - Remote-Field (US) - Senior Medical Science Liaison (ND, SD, MN, IA, MO, NE) Remote-Field (US) About Summit: Summit Therapeutics Inc. is a biopharmaceutical oncology company with a mission focused on improving quality of life, increasing potential duration of life, and resolving serious unmet medical needs. At Summit, we believe in building a team of world class professionals who are passionate about this mission, and it is our people who drive this mission to reality. Summit's core values include integrity, passion for excellence, purposeful urgency, collaboration, and our commitment to people. Our employees are truly the heart and soul of our culture, and they are invaluable in shaping our journey toward excellence. Summit's team is inspired to touch and help change lives through Summit's clinical studies in the field of oncology. Summit has multiple global Phase 3 clinical studies, including: Non-small Cell Lung Cancer (NSCLC) - HARMONi: Phase 3 clinical study which was intended to evaluate ivonescimab combined with chemotherapy compared to placebo plus chemotherapy in patients with EGFR-mutated, locally advanced or metastatic non-squamous NSCLC who were previously treated with a 3rd generation EGFR TKI. - HARMONi-3: Phase 3 clinical study which is intended to evaluate ivonescimab combined with chemotherapy compared to pembrolizumab combined with chemotherapy in patients with first-line metastatic NSCLC. - HARMONi-7: Phase 3 clinical study which is intended to evaluate ivonescimab monotherapy compared to pembrolizumab monotherapy in patients with first-line metastatic NSCLC. Colorectal Cancer (CRC) - HARMONi-GI3: Phase 3 clinical study intended to evaluate ivonescimab in combination with chemotherapy compared with

", "datePosted": "2026-03-09T16:03:35.000Z", "employmentType": "OTHER", "identifier": { "@type": "PropertyValue", "name": "Summit Therapeutics", "value": "2869277bda3611afc254947606e36bbe" }, "hiringOrganization": { "@type": "Organization", "name": "Summit Therapeutics" }, "jobLocationType": "TELECOMMUTE", "applicantLocationRequirements": { "@type": "Country", "name": "USA" }, "estimatedSalary": { "@type": "MonetaryAmount", "currency": "USD", "value": { "@type": "QuantitativeValue", "minValue": 200000, "maxValue": 235000, "unitText": "YEAR" }, "description": "Total compensation" }, "directApply": false, "incentiveCompensation": "Bonus", "experienceRequirements": { "@type": "OccupationalExperienceRequirements", "monthsOfExperience": 60 }, "educationRequirements": "Doctorate", "url": "https://fewerjobs.com/jobs/summit-therapeutics/senior-medical-science-liaison-nd-sd-mn-ia-mo-ne-2869277b" } }, { "@type": "ListItem", "position": 20, "url": "https://fewerjobs.com/jobs/summit-therapeutics/senior-manager-regulatory-affairs-22229cd1", "item": { "@context": "https://schema.org", "@type": "JobPosting", "title": "Senior Manager, Regulatory Affairs", "description": "

Senior Manager, Regulatory Affairs at Summit Therapeutics - Oxford (UK) - Senior Manager, Regulatory Affairs Oxford (UK) About Summit: Summit Therapeutics Inc. is a biopharmaceutical oncology company with a mission focused on improving quality of life, increasing potential duration of life, and resolving serious unmet medical needs. At Summit, we believe in building a team of world class professionals who are passionate about this mission, and it is our people who drive this mission to reality. Summit's core values include integrity, passion for excellence, purposeful urgency, collaboration, and our commitment to people. Our employees are truly the heart and soul of our culture, and they are invaluable in shaping our journey toward excellence. Summit's team is inspired to touch and help change lives through Summit's clinical studies in the field of oncology. Summit has multiple global Phase 3 clinical studies, including: Non-small Cell Lung Cancer (NSCLC) - HARMONi: Phase 3 clinical study which was intended to evaluate ivonescimab combined with chemotherapy compared to placebo plus chemotherapy in patients with EGFR-mutated, locally advanced or metastatic non-squamous NSCLC who were previously treated with a 3rd generation EGFR TKI. - HARMONi-3: Phase 3 clinical study which is intended to evaluate ivonescimab combined with chemotherapy compared to pembrolizumab combined with chemotherapy in patients with first-line metastatic NSCLC. - HARMONi-7: Phase 3 clinical study which is intended to evaluate ivonescimab monotherapy compared to pembrolizumab monotherapy in patients with first-line metastatic NSCLC. Colorectal Cancer (CRC) - HARMONi-GI3: Phase 3 clinical study intended to evaluate ivonescimab in combination with chemotherapy compared with bevacizumab plus chemotherapy. Ivonescimab is an

", "datePosted": "2026-03-09T16:03:32.000Z", "employmentType": "OTHER", "identifier": { "@type": "PropertyValue", "name": "Summit Therapeutics", "value": "22229cd190f37ae8fb872d79488ab713" }, "hiringOrganization": { "@type": "Organization", "name": "Summit Therapeutics" }, "jobLocation": { "@type": "Place", "address": { "@type": "PostalAddress", "addressCountry": "GB" } }, "directApply": false, "incentiveCompensation": "Bonus", "experienceRequirements": { "@type": "OccupationalExperienceRequirements", "monthsOfExperience": 36 }, "educationRequirements": "Doctorate", "url": "https://fewerjobs.com/jobs/summit-therapeutics/senior-manager-regulatory-affairs-22229cd1" } }, { "@type": "ListItem", "position": 21, "url": "https://fewerjobs.com/jobs/summit-therapeutics/senior-director-sales-operations-oncology-8e2f32c3", "item": { "@context": "https://schema.org", "@type": "JobPosting", "title": "Senior Director, Sales Operations (Oncology)", "description": "

Senior Director, Sales Operations (Oncology) at Summit Therapeutics - Princeton, NJ (US) - Senior Director, Sales Operations (Oncology) Princeton, NJ (US) About Summit: Summit Therapeutics Inc. is a biopharmaceutical oncology company with a mission focused on improving quality of life, increasing potential duration of life, and resolving serious unmet medical needs. At Summit, we believe in building a team of world class professionals who are passionate about this mission, and it is our people who drive this mission to reality. Summit's core values include integrity, passion for excellence, purposeful urgency, collaboration, and our commitment to people. Our employees are truly the heart and soul of our culture, and they are invaluable in shaping our journey toward excellence. Summit's team is inspired to touch and help change lives through Summit's clinical studies in the field of oncology. Summit has multiple global Phase 3 clinical studies, including: Non-small Cell Lung Cancer (NSCLC) - HARMONi: Phase 3 clinical study which was intended to evaluate ivonescimab combined with chemotherapy compared to placebo plus chemotherapy in patients with EGFR-mutated, locally advanced or metastatic non-squamous NSCLC who were previously treated with a 3rd generation EGFR TKI. - HARMONi-3: Phase 3 clinical study which is intended to evaluate ivonescimab combined with chemotherapy compared to pembrolizumab combined with chemotherapy in patients with first-line metastatic NSCLC. - HARMONi-7: Phase 3 clinical study which is intended to evaluate ivonescimab monotherapy compared to pembrolizumab monotherapy in patients with first-line metastatic NSCLC. Colorectal Cancer (CRC) - HARMONi-GI3: Phase 3 clinical study intended to evaluate ivonescimab in combination with chemotherapy compared with bevacizumab plus chemotherapy. Ivonescimab

", "datePosted": "2026-03-09T16:03:18.000Z", "employmentType": "OTHER", "identifier": { "@type": "PropertyValue", "name": "Summit Therapeutics", "value": "8e2f32c3935761abab11d36da5dcdc4d" }, "hiringOrganization": { "@type": "Organization", "name": "Summit Therapeutics" }, "jobLocation": { "@type": "Place", "address": { "@type": "PostalAddress", "addressCountry": "US", "addressLocality": "Princeton" } }, "estimatedSalary": { "@type": "MonetaryAmount", "currency": "USD", "value": { "@type": "QuantitativeValue", "minValue": 231000, "maxValue": 285000, "unitText": "YEAR" }, "description": "Total compensation" }, "directApply": false, "incentiveCompensation": "Equity (Options); Bonus", "experienceRequirements": { "@type": "OccupationalExperienceRequirements", "monthsOfExperience": 96 }, "educationRequirements": "Masters", "url": "https://fewerjobs.com/jobs/summit-therapeutics/senior-director-sales-operations-oncology-8e2f32c3" } }, { "@type": "ListItem", "position": 22, "url": "https://fewerjobs.com/jobs/summit-therapeutics/director-safety-physician-5630ab7e", "item": { "@context": "https://schema.org", "@type": "JobPosting", "title": "Director, Safety Physician", "description": "

Director, Safety Physician at Summit Therapeutics - Remote (UK) - Director, Safety Physician Remote (UK) About Summit: Summit Therapeutics Inc. is a biopharmaceutical oncology company with a mission focused on improving quality of life, increasing potential duration of life, and resolving serious unmet medical needs. At Summit, we believe in building a team of world class professionals who are passionate about this mission, and it is our people who drive this mission to reality. Summit's core values include integrity, passion for excellence, purposeful urgency, collaboration, and our commitment to people. Our employees are truly the heart and soul of our culture, and they are invaluable in shaping our journey toward excellence. Summit's team is inspired to touch and help change lives through Summit's clinical studies in the field of oncology. Summit has multiple global Phase 3 clinical studies, including: Non-small Cell Lung Cancer (NSCLC) - HARMONi: Phase 3 clinical study which was intended to evaluate ivonescimab combined with chemotherapy compared to placebo plus chemotherapy in patients with EGFR-mutated, locally advanced or metastatic non-squamous NSCLC who were previously treated with a 3rd generation EGFR TKI. - HARMONi-3: Phase 3 clinical study which is intended to evaluate ivonescimab combined with chemotherapy compared to pembrolizumab combined with chemotherapy in patients with first-line metastatic NSCLC. - HARMONi-7: Phase 3 clinical study which is intended to evaluate ivonescimab monotherapy compared to pembrolizumab monotherapy in patients with first-line metastatic NSCLC. Colorectal Cancer (CRC) - HARMONi-GI3: Phase 3 clinical study intended to evaluate ivonescimab in combination with chemotherapy compared with bevacizumab plus chemotherapy. Ivonescimab is an investigational

", "datePosted": "2026-03-09T16:02:42.000Z", "employmentType": "OTHER", "identifier": { "@type": "PropertyValue", "name": "Summit Therapeutics", "value": "5630ab7e43cf3af968a402fa4929a65e" }, "hiringOrganization": { "@type": "Organization", "name": "Summit Therapeutics" }, "jobLocationType": "TELECOMMUTE", "applicantLocationRequirements": { "@type": "Country", "name": "United Kingdom" }, "directApply": false, "incentiveCompensation": "Bonus", "experienceRequirements": { "@type": "OccupationalExperienceRequirements", "monthsOfExperience": 96 }, "educationRequirements": "no requirements", "url": "https://fewerjobs.com/jobs/summit-therapeutics/director-safety-physician-5630ab7e" } }, { "@type": "ListItem", "position": 23, "url": "https://fewerjobs.com/jobs/summit-therapeutics/director-clinical-scientist-34217c08", "item": { "@context": "https://schema.org", "@type": "JobPosting", "title": "Director, Clinical Scientist", "description": "

Director, Clinical Scientist at Summit Therapeutics - Princeton, NJ (US) - Director, Clinical Scientist Princeton, NJ (US) About Summit: Summit Therapeutics Inc. is a biopharmaceutical oncology company with a mission focused on improving quality of life, increasing potential duration of life, and resolving serious unmet medical needs. At Summit, we believe in building a team of world class professionals who are passionate about this mission, and it is our people who drive this mission to reality. Summit's core values include integrity, passion for excellence, purposeful urgency, collaboration, and our commitment to people. Our employees are truly the heart and soul of our culture, and they are invaluable in shaping our journey toward excellence. Summit's team is inspired to touch and help change lives through Summit's clinical studies in the field of oncology. Summit has multiple global Phase 3 clinical studies, including: Non-small Cell Lung Cancer (NSCLC) - HARMONi: Phase 3 clinical study which was intended to evaluate ivonescimab combined with chemotherapy compared to placebo plus chemotherapy in patients with EGFR-mutated, locally advanced or metastatic non-squamous NSCLC who were previously treated with a 3rd generation EGFR TKI. - HARMONi-3: Phase 3 clinical study which is intended to evaluate ivonescimab combined with chemotherapy compared to pembrolizumab combined with chemotherapy in patients with first-line metastatic NSCLC. - HARMONi-7: Phase 3 clinical study which is intended to evaluate ivonescimab monotherapy compared to pembrolizumab monotherapy in patients with first-line metastatic NSCLC. Colorectal Cancer (CRC) - HARMONi-GI3: Phase 3 clinical study intended to evaluate ivonescimab in combination with chemotherapy compared with bevacizumab plus chemotherapy. Ivonescimab is an

", "datePosted": "2026-03-09T16:02:35.000Z", "employmentType": "OTHER", "identifier": { "@type": "PropertyValue", "name": "Summit Therapeutics", "value": "34217c08575a6538238bad0835e9e308" }, "hiringOrganization": { "@type": "Organization", "name": "Summit Therapeutics" }, "jobLocation": { "@type": "Place", "address": { "@type": "PostalAddress", "addressCountry": "US", "addressLocality": "Princeton" } }, "estimatedSalary": { "@type": "MonetaryAmount", "currency": "USD", "value": { "@type": "QuantitativeValue", "minValue": 200000, "maxValue": 250000, "unitText": "YEAR" }, "description": "Total compensation" }, "directApply": false, "incentiveCompensation": "Bonus", "experienceRequirements": { "@type": "OccupationalExperienceRequirements", "monthsOfExperience": 96 }, "educationRequirements": "Doctorate", "url": "https://fewerjobs.com/jobs/summit-therapeutics/director-clinical-scientist-34217c08" } }, { "@type": "ListItem", "position": 24, "url": "https://fewerjobs.com/jobs/summit-therapeutics/associate-director-biostatistics-a79dbfc0", "item": { "@context": "https://schema.org", "@type": "JobPosting", "title": "Associate Director, Biostatistics", "description": "

Associate Director, Biostatistics at Summit Therapeutics - Palo Alto, California, United States - Associate Director, Biostatistics Palo Alto, California, United States About Summit: Summit Therapeutics Inc. is a biopharmaceutical oncology company with a mission focused on improving quality of life, increasing potential duration of life, and resolving serious unmet medical needs. At Summit, we believe in building a team of world class professionals who are passionate about this mission, and it is our people who drive this mission to reality. Summit's core values include integrity, passion for excellence, purposeful urgency, collaboration, and our commitment to people. Our employees are truly the heart and soul of our culture, and they are invaluable in shaping our journey toward excellence. Summit's team is inspired to touch and help change lives through Summit's clinical studies in the field of oncology. Summit has multiple global Phase 3 clinical studies, including: Non-small Cell Lung Cancer (NSCLC) - HARMONi: Phase 3 clinical study which was intended to evaluate ivonescimab combined with chemotherapy compared to placebo plus chemotherapy in patients with EGFR-mutated, locally advanced or metastatic non-squamous NSCLC who were previously treated with a 3rd generation EGFR TKI. - HARMONi-3: Phase 3 clinical study which is intended to evaluate ivonescimab combined with chemotherapy compared to pembrolizumab combined with chemotherapy in patients with first-line metastatic NSCLC. - HARMONi-7: Phase 3 clinical study which is intended to evaluate ivonescimab monotherapy compared to pembrolizumab monotherapy in patients with first-line metastatic NSCLC. Colorectal Cancer (CRC) - HARMONi-GI3: Phase 3 clinical study intended to evaluate ivonescimab in combination with chemotherapy compared with bevacizumab plus chemotherapy. Ivonescimab

", "datePosted": "2026-03-09T15:59:07.000Z", "employmentType": "OTHER", "identifier": { "@type": "PropertyValue", "name": "Summit Therapeutics", "value": "a79dbfc0c871c37da8dc7173b9ec1dc7" }, "hiringOrganization": { "@type": "Organization", "name": "Summit Therapeutics" }, "jobLocation": { "@type": "Place", "address": { "@type": "PostalAddress", "addressCountry": "US", "addressLocality": "Palo Alto" } }, "estimatedSalary": { "@type": "MonetaryAmount", "currency": "USD", "value": { "@type": "QuantitativeValue", "minValue": 190000, "maxValue": 210000, "unitText": "YEAR" }, "description": "Total compensation" }, "directApply": false, "incentiveCompensation": "Bonus", "experienceRequirements": { "@type": "OccupationalExperienceRequirements", "monthsOfExperience": 96 }, "educationRequirements": "Doctorate", "url": "https://fewerjobs.com/jobs/summit-therapeutics/associate-director-biostatistics-a79dbfc0" } } ] } ] }